Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

INCY

Incyte Corp

Feb 17 • 04:00PM ET

101.16

+0.06 0.06 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN GILD IONS BMY MRK JNJ AMGN PFE LLY

| Held by: VTI VOO VB IVV VBK SPY RSP IBB USMV VFLO

Index	S&P 500	P/E	15.80	EPS (ttm)	6.40	Insider Own	1.02%	Shs Outstand	198.46M	Perf Week	-7.22%
Market Cap	20.13B	Forward P/E	10.83	EPS next Y	9.34	Insider Trans	-13.60%	Shs Float	196.99M	Perf Month	-3.88%
Enterprise Value	16.61B	PEG	0.86	EPS next Q	1.43	Inst Own	103.77%	Short Float	5.68%	Perf Quarter	-4.03%
Income	1.29B	P/S	3.92	EPS this Y	12.85%	Inst Trans	1.47%	Short Ratio	5.40	Perf Half Y	16.38%
Sales	5.14B	P/B	3.89	EPS next Y	21.77%	ROA	20.66%	Short Interest	11.19M	Perf YTD	2.42%
Book/sh	26.04	P/C	5.62	EPS next 5Y	12.63%	ROE	29.87%	52W High	112.29 -9.91%	Perf Year	43.65%
Cash/sh	17.99	P/FCF	14.86	EPS past 3/5Y	61.53% -	ROIC	24.69%	52W Low	53.56 88.87%	Perf 3Y	28.05%
Dividend Est.	-	EV/EBITDA	11.56	Sales past 3/5Y	14.84% 14.03%	Gross Margin	91.47%	Volatility	4.18% 3.50%	Perf 5Y	20.76%
Dividend TTM	-	EV/Sales	3.23	EPS Y/Y TTM	2012.86%	Oper. Margin	26.12%	ATR (14)	3.83	Perf 10Y	35.88%
Dividend Ex-Date	-	Quick Ratio	3.25	Sales Y/Y TTM	21.22%	Profit Margin	25.03%	RSI (14)	47.39	Recom	2.41
Dividend Gr. 3/5Y	- -	Current Ratio	3.32	EPS Q/Q	43.41%	SMA20	-1.35%	Beta	0.84	Target Price	108.81
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	27.84%	SMA50	-0.54%	Rel Volume	0.92	Prev Close	101.10
Employees	2844	LT Debt/Eq	0.01	Earnings	Feb 10 BMO	SMA200	17.97%	Avg Volume	2.07M	Price	101.16
IPO	Nov 04, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.34% 11.22%	Trades		Volume	1,904,974	Change	0.06%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-05-26	Initiated	H.C. Wainwright	Buy	$135
Jan-20-26	Downgrade	Wells Fargo	Overweight → Equal Weight	$107
Dec-08-25	Upgrade	Mizuho	Neutral → Outperform	$121
Nov-03-25	Upgrade	Guggenheim	Neutral → Buy	$125
Oct-08-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-06-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$89
Aug-01-25	Initiated	Barclays	Overweight	$90
Jun-16-25	Upgrade	Stifel	Hold → Buy	$107
Mar-18-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-18-25	Downgrade	Guggenheim	Buy → Neutral
Dec-17-24	Initiated	UBS	Neutral	$77
Oct-29-24	Upgrade	BofA Securities	Neutral → Buy	$68 → $90
Oct-01-24	Initiated	Wolfe Research	Outperform	$84
Sep-18-24	Downgrade	Truist	Buy → Hold	$83 → $74
Jul-02-24	Downgrade	BMO Capital Markets	Market Perform → Underperform	$52 → $48
May-23-24	Initiated	Deutsche Bank	Hold	$55
Apr-23-24	Initiated	Cantor Fitzgerald	Neutral
Feb-23-24	Initiated	Jefferies	Buy	$81
Feb-14-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-13-23	Upgrade	Leerink Partners	Market Perform → Outperform	$78

Show Previous Ratings

Feb-17-26 08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
12:32AM	The Top 5 Analyst Questions From Incyte's Q4 Earnings Call (StockStory)
Feb-12-26 03:24AM	Do Wall Street Analysts Like Incyte Corporation Stock? (Barchart)
Feb-11-26 09:29AM	Company News for Feb 11, 2026 (Zacks)
01:48AM	Analyst Report: Incyte Corporation (Morningstar Research)
12:32AM	Loading…
12:32AM	INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow (StockStory)
Feb-10-26 04:32PM	Broader Market Falls Ahead of Wednesdays US Jobs Report (Barchart) -8.24%
03:50PM	Incyte Q4 Earnings Call Highlights (MarketBeat)
02:03PM	Incyte Corp (INCY) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Pipeline ... (GuruFocus.com)
12:05PM	Why Incyte (INCY) Stock Is Nosediving (StockStory)
11:16AM	Stocks are Mixed After Weak Retail Sales Data Released (Barchart)
10:38AM	INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales (Zacks)
10:06AM	Incyte Crumbles As Light Opzelura Guide Undoes Quarterly Sales Beat (Investor's Business Daily)
09:30AM	Incyte (INCY) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:15AM	Incyte (INCY) Q4 Earnings Lag Estimates (Zacks)
07:35AM	Loading…
07:35AM	Incyte (NASDAQ:INCY) Surprises With Q4 CY2025 Sales (StockStory)
07:24AM	Incyte: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-09-26 11:38AM	Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts? (Zacks)
09:40AM	Here's Why Incyte (INCY) is a Strong Value Stock (Zacks)
Feb-08-26 10:07PM	Incyte (INCY) Q4 Earnings: What To Expect (StockStory)
Feb-06-26 08:23AM	Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards? (Zacks) +5.48%
Feb-05-26 10:12AM	Microsoft downgraded, Snap upgraded: Wall Street's top analyst calls (The Fly)
09:15AM	Unveiling Incyte (INCY) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
07:58AM	Here Are Thursdays Top Wall Street Analyst Research Calls: CAVA Group, DigitalOcean, Fox Corp, Jack Henry, Microsoft, Qualcomm, Snap, Zoom Communications, and More (24/7 Wall St.)
Feb-04-26 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
08:55AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
08:11AM	TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029 (Insider Monkey)
Feb-03-26 10:00AM	Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
05:56AM	Loading…
05:56AM	Analysts Differ in Opinion on Jakafi Drug Maker Incyte (INCY) (Insider Monkey)
Jan-30-26 09:29AM	Incyte Announces Positive CHMP Opinion for Zynyz (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) (Business Wire)
Jan-27-26 08:00AM	Incyte to Report Fourth Quarter and Year-End 2025 Financial Results (Business Wire)
Jan-26-26 09:50AM	Here's Why Incyte (INCY) is a Strong Momentum Stock (Zacks)
Jan-23-26 09:40AM	Why Incyte (INCY) is a Top Value Stock for the Long-Term (Zacks)
Jan-20-26 09:36AM	Intel upgraded, Domino's downgraded: Wall Street's top analyst calls (The Fly)
Jan-14-26 04:20PM	Why Incyte (INCY) Stock Is Trading Up Today (StockStory)
Jan-13-26 06:13PM	Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity (CNBC TV)
09:03AM	Earnings Preview: What To Expect From Incyte's Report (Barchart)
08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jan-12-26 12:10PM	Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? (Zacks)
05:47AM	Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth (Benzinga)
Jan-09-26 11:40AM	This Biotech Stock Eyes Fresh Entry With 522% Earnings Growth Seen (Investor's Business Daily)
04:00AM	Bull of the Day: Eli Lilly (LLY) (Zacks)
Jan-08-26 09:16AM	Rule Breaker Investing Market Cap Game Show: Is Your Favorite Stock in the Spotlight? (Motley Fool)
Jan-07-26 11:21AM	Incyte (INCY) Stock Is Up, What You Need To Know (StockStory)
08:55AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Jan-06-26 10:19AM	INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma (Zacks)
Jan-05-26 07:30AM	Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi/Minjuvi) as a First-line Treatment for Diffuse Large B-Cell Lymphoma (Business Wire)
Dec-27-25 08:00AM	Palantir, Nvidia Lead 5 Stocks Near Buy Points Heading Into Final Days Of 2025 (Investor's Business Daily)
Dec-22-25 09:03AM	Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
02:44AM	Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma (Business Wire)
02:42AM	Incyte Japan Announces Approval of Zynyz (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer (Business Wire)
Dec-18-25 09:30AM	EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi (Zacks)
08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
06:56AM	EC approves Incyte's Minjuvi combo for follicular lymphoma (Pharmaceutical Business Review)
Dec-17-25 11:20AM	Incyte Announces European Commission Approval of Minjuvi (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (Business Wire)
Dec-15-25 08:21AM	Is Incyte Stock Outperforming the Nasdaq? (Barchart)
Dec-12-25 08:30AM	Incyte Announces Change to its Board of Directors (Business Wire)
Dec-11-25 09:40AM	Here's Why Incyte (INCY) is a Strong Value Stock (Zacks)
Dec-09-25 01:23PM	Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack (CNBC TV)
Dec-08-25 04:30PM	Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia (Business Wire) -5.68%
10:30AM	Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status (Zacks)
09:45AM	Incyte Stock Falls Despite FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug (Investor's Business Daily)
07:10AM	Incyte Stock Rises On FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug (Investor's Business Daily)
Dec-07-25 09:30AM	Incytes First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA (Business Wire)
09:30AM	Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025 (Business Wire)
Dec-03-25 04:30PM	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-02-25 09:15AM	Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding (Business Wire)
Nov-27-25 11:30AM	Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-20-25 09:50AM	Why Incyte (INCY) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-19-25 09:41AM	Why Incyte (INCY) is a Top Value Stock for the Long-Term (Zacks)
08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
Nov-17-25 01:00AM	Incyte Announces Positive CHMP Opinion for Minjuvi (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL) (Business Wire)
Nov-14-25 07:30AM	Incyte Stock Outlook: Is Wall Street Bullish or Bearish? (Barchart)
Nov-12-25 01:33PM	Ocular Therapeutix Stock Earns 81 RS Rating (Investor's Business Daily)
Nov-10-25 10:31PM	Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack (StockStory)
Nov-07-25 01:18PM	Halozyme Therapeutics Stock Sees Improved RS Rating (Investor's Business Daily)
Nov-06-25 09:15AM	Incytes Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema (Business Wire)
Nov-05-25 11:01PM	Incyte (INCY): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Nov-04-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
06:18AM	Incyte (INCY) Extends Climb, Hits New High on Bullish Coverage (Insider Monkey)
12:38AM	The 5 Most Interesting Analyst Questions From Incyte's Q3 Earnings Call (StockStory)
Nov-03-25 07:38PM	Analyst Report: Incyte Corporation (Morningstar Research) +8.65%
09:31AM	Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting (Business Wire)
Oct-30-25 03:04PM	Incyte Corp (INCY) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
09:36AM	Analyst Report: Incyte Corporation (Morningstar Research)
08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
Oct-29-25 01:31AM	INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus (StockStory)
Oct-28-25 02:42PM	1 Growth Stock Under $100 to Buy Before It Soars (Barchart)
12:24PM	Bank of America Securities Maintains a Buy on Incyte Corporation (INCY) (Insider Monkey)
12:11PM	Why Incyte (INCY) Stock Is Trading Lower Today (StockStory)
11:09AM	INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales (Zacks)
09:49AM	Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views (Investor's Business Daily)
09:30AM	Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:15AM	Incyte (INCY) Tops Q3 Earnings and Revenue Estimates (Zacks)
07:18AM	Incyte (NASDAQ:INCY) Reports Strong Q3 (StockStory)
07:10AM	Incyte: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Oct-27-25 12:44PM	ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards? (Zacks)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VIJAY IYENGAR	Officer	Feb 09 '26	Proposed Sale	109.00	12,743	1,388,987		Feb 09 05:14 PM
Issa Mohamed Khairie	EVP, Head of US Oncology	Jan 07 '26	Sale	109.07	10,856	1,184,064	66,132	Jan 08 04:03 PM
Stein Steven H	EVP & Chief Medical Officer	Jan 05 '26	Sale	101.70	15,634	1,589,978	34,203	Jan 07 04:03 PM
MOHAMED ISSA	Officer	Jan 07 '26	Proposed Sale	109.07	10,856	1,184,051		Jan 07 04:01 PM
VIJAY IYENGAR	Officer	Jan 06 '26	Proposed Sale	104.35	95,811	9,998,256		Jan 06 04:05 PM
VIJAY IYENGAR	Officer	Jan 05 '26	Proposed Sale	102.81	16,437	1,689,888		Jan 05 04:34 PM
STEVEN STEIN	Officer	Jan 05 '26	Proposed Sale	101.70	15,634	1,589,995		Jan 05 04:06 PM
Tray Thomas	Principal Accounting Officer	Dec 19 '25	Option Exercise	95.76	2,774	265,638	25,747	Dec 22 08:46 PM
Tray Thomas	Principal Accounting Officer	Dec 19 '25	Sale	100.00	2,774	277,400	22,973	Dec 22 08:46 PM
Tray Thomas	Principal Accounting Officer	Dec 18 '25	Sale	98.25	600	58,950	22,973	Dec 22 08:46 PM
VIJAY IYENGAR	Officer	Dec 19 '25	Proposed Sale	101.73	52,941	5,385,677		Dec 19 04:06 PM
THOMAS R TRAY	Officer	Dec 19 '25	Proposed Sale	100.00	2,774	277,400		Dec 19 04:05 PM
THOMAS R TRAY	Officer	Dec 18 '25	Proposed Sale	98.25	600	58,950		Dec 18 04:12 PM
Morrissey Michael James	EVP, Head of Tech. Operations	Dec 16 '25	Sale	97.29	54,008	5,254,547	31,830	Dec 18 04:11 PM
Morrissey Michael James	EVP, Head of Tech. Operations	Dec 17 '25	Sale	97.26	4,323	420,455	27,507	Dec 18 04:11 PM
MICHAEL MORRISSEY	Officer	Dec 17 '25	Proposed Sale	97.26	4,323	420,455		Dec 17 04:01 PM
VIJAY IYENGAR	Officer	Dec 16 '25	Proposed Sale	98.39	13,388	1,317,245		Dec 16 04:53 PM
MICHAEL MORRISSEY	Officer	Dec 16 '25	Proposed Sale	97.29	54,008	5,254,458		Dec 16 04:15 PM
CHRISTIANA STAMOULIS	Officer	Dec 15 '25	Proposed Sale	97.00	187,690	18,205,930		Dec 15 05:31 PM
Mayes Patrick A	EVP & Chief Scientific Officer	Dec 10 '25	Sale	95.58	5,553	530,756	60,266	Dec 12 04:01 PM
Mayes Patrick A	EVP & Chief Scientific Officer	Dec 11 '25	Sale	94.94	255	24,210	60,011	Dec 12 04:01 PM
PATRICK A MAYES	Officer	Dec 11 '25	Proposed Sale	94.94	255	24,210		Dec 11 04:13 PM
VIJAY IYENGAR	Officer	Dec 10 '25	Proposed Sale	95.51	23,104	2,206,695		Dec 10 05:29 PM
PATRICK A MAYES	Officer	Dec 10 '25	Proposed Sale	95.58	5,553	530,756		Dec 10 04:04 PM
Stein Steven H	EVP & Chief Medical Officer	Dec 02 '25	Sale	102.51	20,105	2,060,964	63,129	Dec 03 04:36 PM
Stein Steven H	EVP & Chief Medical Officer	Dec 01 '25	Sale	102.96	2,559	263,475	100,327	Dec 03 04:36 PM
STEVEN STEIN	Officer	Dec 02 '25	Proposed Sale	102.51	20,105	2,060,978		Dec 02 04:04 PM
STEVEN STEIN	Officer	Dec 01 '25	Proposed Sale	102.96	2,559	263,482		Dec 01 04:05 PM
Tray Thomas	Principal Accounting Officer	Nov 24 '25	Sale	103.00	600	61,800	23,573	Nov 25 04:02 PM
Tray Thomas	Principal Accounting Officer	Nov 21 '25	Sale	102.00	169	17,238	24,173	Nov 25 04:02 PM
THOMAS R TRAY	Officer	Nov 24 '25	Proposed Sale	103.00	600	61,800		Nov 24 04:13 PM
THOMAS R TRAY	Officer	Nov 21 '25	Proposed Sale	102.00	169	17,238		Nov 21 04:17 PM
Denton Sheila A.	EVP & General Counsel	Nov 17 '25	Option Exercise	64.25	278	17,862	26,847	Nov 19 04:08 PM
Denton Sheila A.	EVP & General Counsel	Nov 17 '25	Sale	104.36	278	29,012	26,569	Nov 19 04:08 PM
SHEILA DENTON	Officer	Nov 17 '25	Proposed Sale	104.36	278	29,012		Nov 17 04:01 PM
Hoppenot Herve	Director	Nov 10 '25	Sale	105.46	187,500	19,773,750	329,646	Nov 12 04:06 PM
CHRISTIANA STAMOULIS	Officer	Nov 12 '25	Proposed Sale	109.00	7,442	811,178		Nov 12 04:06 PM
HERVE HOPPENOT	Officer	Nov 10 '25	Proposed Sale	105.46	187,500	19,773,454		Nov 10 06:14 PM
Stein Steven H	EVP & Chief Medical Officer	Nov 05 '25	Option Exercise	93.04	5,233	486,868	108,119	Nov 07 04:01 PM
Stein Steven H	EVP & Chief Medical Officer	Nov 05 '25	Sale	102.20	5,233	534,813	102,886	Nov 07 04:01 PM
Denton Sheila A.	EVP & General Counsel	Nov 04 '25	Option Exercise	58.06	598	34,720	27,167	Nov 06 04:01 PM
Denton Sheila A.	EVP & General Counsel	Nov 04 '25	Sale	101.36	598	60,613	26,569	Nov 06 04:01 PM
STEVEN STEIN	Officer	Nov 05 '25	Proposed Sale	102.20	5,233	534,813		Nov 05 04:37 PM
Heeson Lee	EVP, Head of Incyte Intl	Nov 03 '25	Sale	94.02	3,074	289,017	29,241	Nov 05 04:12 PM
SHEILA DENTON	Officer	Nov 04 '25	Proposed Sale	101.36	598	60,613		Nov 04 04:09 PM
CHRISTIANA STAMOULIS	Officer	Nov 03 '25	Proposed Sale	97.74	22,113	2,161,367		Nov 03 04:11 PM
LEE HEESON	Officer	Nov 03 '25	Proposed Sale	94.02	3,074	289,017		Nov 03 04:02 PM
CHRISTIANA STAMOULIS	Officer	Oct 30 '25	Proposed Sale	94.00	14,986	1,408,684		Oct 30 04:31 PM
BARRY FLANNELLY	Officer	Oct 27 '25	Proposed Sale	91.73	33,452	3,068,539		Oct 27 04:21 PM
Denton Sheila A.	EVP & General Counsel	Oct 15 '25	Option Exercise	64.25	277	17,797	26,846	Oct 17 04:01 PM
Denton Sheila A.	EVP & General Counsel	Oct 15 '25	Sale	85.13	277	23,581	26,569	Oct 17 04:01 PM
BARRY FLANNELLY	Officer	Oct 16 '25	Proposed Sale	92.38	18,495	1,708,609		Oct 16 04:01 PM
SHEILA DENTON	Officer	Oct 15 '25	Proposed Sale	85.13	277	23,581		Oct 15 04:03 PM
Denton Sheila A.	EVP & General Counsel	Oct 02 '25	Option Exercise	58.06	599	34,778	33,799	Oct 06 04:02 PM
Denton Sheila A.	EVP & General Counsel	Oct 03 '25	Sale	85.54	3,501	299,476	26,569	Oct 06 04:02 PM
Denton Sheila A.	EVP & General Counsel	Oct 02 '25	Sale	87.65	599	52,502	33,200	Oct 06 04:02 PM
SHEILA DENTON	Officer	Oct 03 '25	Proposed Sale	85.54	3,501	299,464		Oct 03 04:07 PM
SHEILA DENTON	Officer	Oct 02 '25	Proposed Sale	87.65	599	52,502		Oct 02 04:01 PM
BARRY FLANNELLY	Officer	Sep 18 '25	Proposed Sale	85.26	17,447	1,487,531		Sep 18 05:10 PM
Denton Sheila A.	EVP & General Counsel	Sep 16 '25	Option Exercise	64.25	278	17,862	33,478	Sep 18 04:06 PM
Denton Sheila A.	EVP & General Counsel	Sep 16 '25	Sale	83.15	278	23,116	33,200	Sep 18 04:06 PM
SHEILA DENTON	Officer	Sep 16 '25	Proposed Sale	83.15	278	23,116		Sep 16 04:03 PM
Denton Sheila A.	EVP & General Counsel	Sep 02 '25	Option Exercise	58.06	598	34,720	33,798	Sep 04 04:04 PM
Denton Sheila A.	EVP & General Counsel	Sep 02 '25	Sale	84.97	598	50,812	33,200	Sep 04 04:04 PM
SHEILA DENTON	Officer	Sep 02 '25	Proposed Sale	84.97	598	50,812		Sep 02 04:07 PM
Denton Sheila A.	EVP & General Counsel	Aug 15 '25	Option Exercise	64.25	277	17,797	33,477	Aug 19 04:13 PM
Denton Sheila A.	EVP & General Counsel	Aug 15 '25	Sale	86.81	277	24,046	33,200	Aug 19 04:13 PM
SHEILA DENTON	Officer	Aug 15 '25	Proposed Sale	86.81	277	24,046		Aug 15 04:05 PM
BARRY FLANNELLY	Officer	Aug 13 '25	Proposed Sale	82.51	75,963	6,267,540		Aug 13 04:18 PM
BARRY FLANNELLY	Officer	Aug 12 '25	Proposed Sale	80.00	14,037	1,122,970		Aug 12 04:21 PM
Denton Sheila A.	EVP & General Counsel	Aug 04 '25	Option Exercise	58.06	598	34,720	33,798	Aug 06 04:03 PM
Denton Sheila A.	EVP & General Counsel	Aug 04 '25	Sale	75.77	598	45,310	33,200	Aug 06 04:03 PM
SHEILA DENTON	Officer	Aug 04 '25	Proposed Sale	75.77	598	45,310		Aug 04 04:05 PM
Stein Steven H	EVP & Chief Medical Officer	Jul 21 '25	Sale	67.94	3,706	251,786	102,886	Jul 23 03:56 PM
STEVEN STEIN	Officer	Jul 21 '25	Proposed Sale	67.94	3,706	251,786		Jul 21 04:01 PM
Flannelly Barry P	EVP & General Manager US	Jul 16 '25	Sale	68.36	1,340	91,602	35,149	Jul 17 04:06 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 16 '25	Sale	68.36	983	67,198	40,540	Jul 17 04:05 PM
Denton Sheila A.	EVP & General Counsel	Jul 15 '25	Option Exercise	64.25	3,330	213,952	29,834	Jul 17 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jul 15 '25	Sale	69.86	3,330	232,634	26,504	Jul 17 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jul 16 '25	Sale	68.36	785	53,663	33,200	Jul 17 04:04 PM
VIJAY IYENGAR	Officer	Jul 16 '25	Proposed Sale	68.36	983	67,198		Jul 16 04:07 PM
BARRY FLANNELLY	Officer	Jul 16 '25	Proposed Sale	68.36	1,340	91,602		Jul 16 04:06 PM
Stein Steven H	EVP & Chief Medical Officer	Jul 14 '25	Sale	68.47	14,952	1,023,763	97,466	Jul 16 04:05 PM
SHEILA DENTON	Officer	Jul 16 '25	Proposed Sale	68.36	785	53,663		Jul 16 04:02 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 15 '25	Sale	69.86	1,177	82,225	35,929	Jul 16 04:02 PM
Flannelly Barry P	EVP & General Manager US	Jul 15 '25	Sale	69.86	1,192	83,273	37,630	Jul 16 04:02 PM
BARRY FLANNELLY	Officer	Jul 15 '25	Proposed Sale	69.86	1,192	83,273		Jul 15 04:41 PM
SHEILA DENTON	Officer	Jul 15 '25	Proposed Sale	69.86	3,330	232,634		Jul 15 04:37 PM
VIJAY IYENGAR	Officer	Jul 15 '25	Proposed Sale	69.86	1,177	82,225		Jul 15 04:20 PM
STEVEN STEIN	Officer	Jul 14 '25	Proposed Sale	68.47	14,952	1,023,714		Jul 14 04:03 PM
Flannelly Barry P	EVP & General Manager US	Jul 03 '25	Sale	68.15	10,903	743,039	39,744	Jul 07 04:46 PM
Denton Sheila A.	EVP & General Counsel	Jul 02 '25	Option Exercise	58.06	599	34,778	27,103	Jul 07 04:44 PM
Denton Sheila A.	EVP & General Counsel	Jul 02 '25	Sale	68.61	599	41,097	26,504	Jul 07 04:44 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 03 '25	Sale	68.15	8,617	587,275	37,701	Jul 07 04:43 PM
BARRY FLANNELLY	Officer	Jul 03 '25	Proposed Sale	68.15	10,903	743,048		Jul 03 03:10 PM
VIJAY IYENGAR	Officer	Jul 03 '25	Proposed Sale	68.15	8,617	587,272		Jul 03 02:46 PM
SHEILA DENTON	Officer	Jul 02 '25	Proposed Sale	68.61	599	41,097		Jul 02 04:27 PM
Denton Sheila A.	EVP & General Counsel	Jun 03 '25	Option Exercise	58.06	1,795	104,218	28,299	Jun 05 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jun 03 '25	Sale	68.00	1,795	122,060	26,504	Jun 05 04:04 PM
SHEILA DENTON	Officer	Jun 03 '25	Proposed Sale	68.00	1,795	122,060		Jun 03 04:06 PM

Open in Screener

NOTV

Inotiv Inc

Feb 17 • 04:00PM ET

0.2920

+0.0072 2.53 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: CRL ICON IQV MEDP CROX CERS BMRN CTLT EXEL NBIX

| Held by: VTI VXF IWC PRFZ

Index	-	P/E	-	EPS (ttm)	-2.02	Insider Own	9.56%	Shs Outstand	34.39M	Perf Week	-19.18%
Market Cap	10.04M	Forward P/E	-	EPS next Y	-1.81	Insider Trans	-3.56%	Shs Float	31.11M	Perf Month	-48.55%
Enterprise Value	473.28M	PEG	-	EPS next Q	-0.64	Inst Own	21.55%	Short Float	6.46%	Perf Quarter	-72.19%
Income	-69.37M	P/S	0.02	EPS this Y	-7.35%	Inst Trans	-0.45%	Short Ratio	3.02	Perf Half Y	-84.55%
Sales	514.03M	P/B	0.09	EPS next Y	20.09%	ROA	-9.21%	Short Interest	2.01M	Perf YTD	-48.05%
Book/sh	3.17	P/C	0.79	EPS next 5Y	-	ROE	-49.76%	52W High	4.51 -93.53%	Perf Year	-92.28%
Cash/sh	0.37	P/FCF	-	EPS past 3/5Y	46.54% -37.40%	ROIC	-41.61%	52W Low	0.28 4.51%	Perf 3Y	-96.06%
Dividend Est.	-	EV/EBITDA	24.30	Sales past 3/5Y	-2.15% 53.36%	Gross Margin	12.69%	Volatility	11.37% 11.06%	Perf 5Y	-98.30%
Dividend TTM	-	EV/Sales	0.92	EPS Y/Y TTM	56.09%	Oper. Margin	-7.01%	ATR (14)	0.05	Perf 10Y	-75.67%
Dividend Ex-Date	-	Quick Ratio	0.21	Sales Y/Y TTM	8.19%	Profit Margin	-13.50%	RSI (14)	22.14	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.30	EPS Q/Q	18.83%	SMA20	-34.53%	Beta	4.24	Target Price	3.25
Payout	-	Debt/Eq	4.37	Sales Q/Q	0.84%	SMA50	-49.29%	Rel Volume	0.45	Prev Close	0.28
Employees	2046	LT Debt/Eq	0.53	Earnings	Feb 09 BMO	SMA200	-79.79%	Avg Volume	665.43K	Price	0.29
IPO	Nov 25, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	-30.09% -0.02%	Trades		Volume	371,553	Change	2.53%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-24	Downgrade	Jefferies	Buy → Hold	$11.50 → $3.75
Feb-09-24	Upgrade	Jefferies	Hold → Buy	$3 → $11.50
Jul-20-23	Initiated	Wells Fargo	Overweight	$9
Jan-19-23	Downgrade	Jefferies	Buy → Hold	$10 → $8
Jan-11-23	Upgrade	Lake Street	Hold → Buy	$4 → $10
Nov-18-22	Downgrade	Lake Street	Buy → Hold	$60 → $7
Oct-04-22	Initiated	Jefferies	Buy	$27
Jan-31-22	Initiated	Lake Street	Buy	$60
Sep-20-21	Initiated	Craig Hallum	Buy	$45

Feb-16-26 08:01PM	Inotiv Inc (NOTV) Q1 2026 Earnings Call Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
Feb-13-26 04:30PM	Inotiv Provides Notice Regarding Cybersecurity Incident (GlobeNewswire)
Feb-09-26 07:00AM	Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update (GlobeNewswire) -13.63%
Feb-04-26 06:30AM	Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026 (GlobeNewswire) -6.83%
Jan-13-26 09:15AM	Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery (GlobeNewswire)
09:00AM	Loading…
Dec-11-25 09:00AM	Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities (GlobeNewswire)
Dec-04-25 06:05PM	Inotiv Inc (NOTV) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Cybersecurity Challenges (GuruFocus.com) -6.53% -8.10%
Dec-03-25 04:05PM	Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update (GlobeNewswire) +8.13%
Nov-25-25 07:00AM	Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500 (GlobeNewswire)
Nov-21-25 07:00AM	Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025 (GlobeNewswire)
Nov-17-25 04:05PM	Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results (GlobeNewswire) -33.20% +24.62%
Oct-24-25 10:20AM	Halper Sadeh LLC Encourages Inotiv, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-21-25 04:05PM	Inotiv, Inc. to Participate in Three Investor Conferences in November 2025 (GlobeNewswire)
Aug-20-25 07:37AM	Pharmaceutical firm Inotiv investigating ransomware attack that disrupted operations (Cybersecurity Dive)
Aug-13-25 07:00AM	Inotiv, Inc. to Participate in Three Investor Conferences in September 2025 (GlobeNewswire)
09:16PM	Loading…
Aug-06-25 09:16PM	CORRECTING and REPLACING - Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update (GlobeNewswire) +5.54% -10.50%
05:50PM	Inotiv, Inc. (NOTV) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update (GlobeNewswire)
Aug-05-25 07:15AM	Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-23-25 07:00AM	Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025 (GlobeNewswire) +7.14%
May-22-25 04:05PM	Inotiv, Inc. to Present at Jefferies Global Healthcare Conference 2025 (GlobeNewswire)
May-08-25 03:28AM	Inotiv Inc (NOTV) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Optimizations ... (GuruFocus.com) +10.20%
12:05AM	Inotiv outlines revised RMS site optimization plan with $6.5M investment and $6M-$7M annual savings projection (Seeking Alpha)
12:03AM	Inotiv, Inc. (NOTV) Q2 2025 Earnings Call Transcript (Seeking Alpha)
May-07-25 06:45PM	Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +14.20%
04:05PM	Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update (GlobeNewswire)
May-06-25 08:45AM	Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates (Zacks) -13.73%
May-01-25 10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-30-25 10:01AM	Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-23-25 04:05PM	Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025 (GlobeNewswire) +7.27% +8.47%
02:14AM	Loading…
Feb-06-25 02:14AM	Inotiv Inc (NOTV) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... (GuruFocus.com) -6.22%
Feb-05-25 04:05PM	Inotiv Reports First Quarter Financial Results for Fiscal 2025 and Provides Business Update (GlobeNewswire) -7.01%
Jan-22-25 04:05PM	Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025 (GlobeNewswire)
Dec-30-24 04:05PM	Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million (GlobeNewswire) -11.06%
Dec-23-24 04:05PM	Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million (GlobeNewswire) +14.97%
Dec-18-24 08:00AM	Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares (GlobeNewswire) -28.83%
Dec-17-24 04:03PM	Inotiv, Inc. Launches Proposed Public Offering of Common Shares (GlobeNewswire)
Dec-04-24 02:00AM	Inotiv Inc (NOTV) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Operational Challenges (GuruFocus.com) -6.21%
Dec-03-24 04:05PM	Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire) +7.44%
Dec-02-24 07:02AM	Inotiv Inc (NOTV) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +6.56%
Nov-21-24 08:30AM	Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500 (GlobeNewswire) +6.23%
Nov-20-24 04:05PM	Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024 (GlobeNewswire) +15.05%
Nov-07-24 08:00AM	Inotiv, Inc. to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences (GlobeNewswire) +8.23%
Oct-09-24 05:54PM	Inotiv Inc (NOTV) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... (GuruFocus.com)
Sep-16-24 08:00AM	Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity (GlobeNewswire) +18.97%
Aug-28-24 04:05PM	Inotiv to Participate in the 8th Annual Lake Street Best Ideas Growth Conference (GlobeNewswire) +9.29%
Aug-08-24 06:15PM	Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +5.66%
04:05PM	Inotiv Reports Third Quarter Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire)
Jul-25-24 08:00AM	Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024 (GlobeNewswire)
Jul-09-24 06:50AM	3 Breakout Stocks to Buy Before They Make Headlines (InvestorPlace)
Jul-01-24 10:20AM	3 Undervalued Stocks Primed for a 2X Return (InvestorPlace)
Jun-10-24 07:30AM	Inotiv, Inc. Provides Business Updates (GlobeNewswire) +6.43%
Jun-03-24 02:49PM	Company that bred beagles for research pleads guilty to neglect, ordered to pay record $35M fine (Associated Press Finance) +16.04%
01:24PM	Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility (GlobeNewswire)
May-23-24 04:15PM	Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences (GlobeNewswire)
May-15-24 09:54PM	NOTV Stock Earnings: Inotiv Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace) +5.66%
04:05PM	Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire)
May-14-24 08:19AM	Why Is Inotiv (NOTV) Stock Down 35% Today? (InvestorPlace) -49.16%
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Wednesday, May 15, 2024 (GlobeNewswire)
May-10-24 05:20AM	Inotiv Delays Release of Fiscal Q2 Results (MT Newswires) -9.62%
May-09-24 06:56PM	Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results (GlobeNewswire) -12.42%
Apr-29-24 04:05PM	Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Friday, May 10, 2024 (GlobeNewswire) -7.65%
Apr-03-24 08:50AM	Inotiv (NOTV) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Apr-02-24 08:50AM	Why Fast-paced Mover Inotiv (NOTV) Is a Great Choice for Value Investors (Zacks)
Mar-25-24 09:40AM	Is Inotiv (NOTV) a Great Value Stock Right Now? (Zacks)
Mar-18-24 08:50AM	Here's Why Momentum in Inotiv, Inc. (NOTV) Should Keep going (Zacks)
Mar-12-24 04:42PM	Rocket Stocks: 3 Picks That Could Skyrocket Your Portfolio by 2025 (InvestorPlace) +9.96%
Mar-07-24 04:20PM	3 Stocks That Could Fast-Track Your Millionaire Status (InvestorPlace) +6.54%
12:00PM	Inotiv, Inc. (NOTV) is a Great Momentum Stock: Should You Buy? (Zacks)
08:50AM	Despite Fast-paced Momentum, Inotiv, Inc. (NOTV) Is Still a Bargain Stock (Zacks)
Mar-01-24 09:40AM	Should Value Investors Buy Inotiv (NOTV) Stock? (Zacks) +7.25%
Feb-29-24 08:50AM	Here's What Could Help Inotiv, Inc. (NOTV) Maintain Its Recent Price Strength (Zacks) +13.57%
Feb-27-24 01:34PM	3 Overlooked Stocks with Potential for 500% Growth by 2025 (InvestorPlace)
Feb-20-24 07:38AM	Millionaire-Makers: 3 Game-Changing Stocks Ready for Historic Gains (InvestorPlace) +6.52%
Feb-19-24 08:50AM	Inotiv, Inc. (NOTV) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
Feb-14-24 09:40AM	Are Investors Undervaluing Inotiv (NOTV) Right Now? (Zacks) +10.23%
Feb-09-24 08:25AM	Inotiv, Inc. (NASDAQ:NOTV) Q1 2024 Earnings Call Transcript (Insider Monkey) +15.35%
Feb-08-24 09:55AM	Inotiv Inc (NOTV) Reports Revenue Growth and Reduced Net Loss in Q1 FY 2024 (GuruFocus.com) +16.85%
08:54AM	Q1 2024 Inotiv Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-07-24 06:10PM	Inotiv, Inc. (NOTV) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire)
Jan-29-24 04:05PM	Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024 (GlobeNewswire) -5.22%
Jan-27-24 09:00AM	Big Pharmas great lab monkey shortage: A crackdown on smuggling is causing chaos in Americas vital drug development pipeline (Fortune)
Dec-16-23 03:01PM	Insider Buying: COO John Beattie Acquires 47,966 Shares of Inotiv Inc (NOTV) (GuruFocus.com)
Dec-15-23 08:50AM	Inotiv, Inc. (NOTV) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Dec-14-23 08:14AM	Inotiv, Inc. (NASDAQ:NOTV) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.32%
Dec-12-23 07:45AM	Q4 2023 Inotiv Inc Earnings Call (Thomson Reuters StreetEvents) -15.84%
Dec-11-23 09:54PM	NOTV Stock Earnings: Inotiv Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.36%
04:05PM	Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update (GlobeNewswire)
Dec-06-23 04:30PM	Inotiv, Inc. Announces Plan to Insource North American Transportation Operations (GlobeNewswire) +14.55%
Nov-27-23 04:05PM	Inotiv, Inc. to Report Fiscal 2023 Fourth Quarter and Full Year Results and Host Conference Call on Monday, December 11, 2023 (GlobeNewswire) -13.73% +6.12%
Nov-13-23 04:05PM	Inotiv Provides Business Updates and Upcoming Investor Conferences Update (GlobeNewswire) +16.48%
Nov-08-23 07:30AM	Inotiv Ranked Number 127 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 (GlobeNewswire)
Nov-01-23 08:00AM	Inotiv, Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-16-23 08:00AM	Inotiv, Inc. Announces Changes to its Board Composition (GlobeNewswire) +21.95%
Aug-29-23 06:47PM	Inotiv Announces the Sale of its Israeli Businesses to Harlan Holdings Ltd. (GlobeNewswire)
Aug-24-23 04:05PM	Inotiv, Inc. to Participate in Upcoming September 2023 Investor Conferences (GlobeNewswire) -6.55%
Aug-15-23 03:31PM	Inotiv Faces SEC Probe on Imports of Monkeys From Asia (The Wall Street Journal) -6.86%
Aug-10-23 06:15PM	Inotiv, Inc. (NOTV) Q3 Earnings Miss Estimates (Zacks) -35.63%

Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Leasure Robert Jr.	Officer	Feb 17 '26	Proposed Sale	0.29	20,000	5,800		Feb 17 12:25 PM
Leasure Robert Jr.	President and CEO	Feb 02 '26	Sale	0.50	113,297	57,034	1,273,025	Feb 03 04:14 PM
Leasure Robert Jr.	Officer	Feb 02 '26	Proposed Sale	0.49	120,000	59,088		Feb 02 02:31 PM
Neff R Matthew	Director	Dec 01 '25	Sale	0.89	2,000	1,771	151,102	Dec 02 04:41 PM
Neff R Matthew	Director	Dec 01 '25	Proposed Sale	0.89	2,000	1,771		Dec 01 11:29 AM
Neff R Matthew	Director	Nov 03 '25	Sale	1.24	2,000	2,487	153,102	Nov 04 05:16 PM
Neff R Matthew	Director	Oct 24 '25	Option Exercise	1.94	10,000	19,400	155,102	Oct 28 04:03 PM
Neff R Matthew	Director	Oct 01 '25	Sale	1.43	2,000	2,858	145,102	Oct 03 04:25 PM
Neff R Matthew	Director	Sep 02 '25	Sale	1.67	2,000	3,338	147,102	Sep 04 10:46 AM
Neff R Matthew	Director	Sep 02 '25	Proposed Sale	1.67	6,000	10,000		Sep 02 11:24 AM
Neff R Matthew	Director	Aug 01 '25	Sale	1.91	2,000	3,818	149,102	Aug 04 04:28 PM
Neff R Matthew	Director	Jul 01 '25	Sale	1.81	2,000	3,621	151,102	Jul 03 04:30 PM
Neff R Matthew	Director	Jun 02 '25	Sale	2.62	2,000	5,246	153,102	Jun 04 04:05 PM
Neff R Matthew	Director	Jun 02 '25	Proposed Sale	2.60	6,000	15,600		Jun 02 10:26 AM
Coelho Mary Theresa	Director	Apr 01 '25	Sale	2.35	5,500	12,916	74,303	Apr 02 04:32 PM
Coelho Mary Theresa	Director	Apr 01 '25	Proposed Sale	2.83	5,500	15,565		Apr 01 06:33 PM

CRL Charles River Laboratories International Inc daily Stock Chart

Peers: IQV LDOS MEDP CVS PFE ILMN BMY LH MRK

| Held by: VTI VOO VB VBR RSP IVV SPY XLV IBB DFAT

Index	S&P 500	P/E	-	EPS (ttm)	-1.55	Insider Own	1.26%	Shs Outstand	49.22M	Perf Week	-14.63%
Market Cap	7.80B	Forward P/E	14.55	EPS next Y	10.89	Insider Trans	-0.19%	Shs Float	48.60M	Perf Month	-29.06%
Enterprise Value	10.27B	PEG	2.81	EPS next Q	2.34	Inst Own	108.84%	Short Float	5.53%	Perf Quarter	-6.31%
Income	-83.48M	P/S	1.94	EPS this Y	-0.84%	Inst Trans	4.34%	Short Ratio	3.28	Perf Half Y	1.18%
Sales	4.02B	P/B	2.29	EPS next Y	6.45%	ROA	-1.08%	Short Interest	2.69M	Perf YTD	-20.53%
Book/sh	69.20	P/C	37.57	EPS next 5Y	5.17%	ROE	-2.32%	52W High	228.88 -30.74%	Perf Year	4.30%
Cash/sh	4.22	P/FCF	14.35	EPS past 3/5Y	-70.29% -47.65%	ROIC	-1.38%	52W Low	91.86 72.58%	Perf 3Y	-36.53%
Dividend Est.	-	EV/EBITDA	11.32	Sales past 3/5Y	4.59% 9.09%	Gross Margin	29.73%	Volatility	6.78% 4.60%	Perf 5Y	-47.06%
Dividend TTM	-	EV/Sales	2.55	EPS Y/Y TTM	-118.96%	Oper. Margin	11.94%	ATR (14)	9.08	Perf 10Y	116.28%
Dividend Ex-Date	-	Quick Ratio	1.10	Sales Y/Y TTM	-0.92%	Profit Margin	-2.07%	RSI (14)	23.94	Recom	2.06
Dividend Gr. 3/5Y	- -	Current Ratio	1.37	EPS Q/Q	-17.30%	SMA20	-20.14%	Beta	1.67	Target Price	225.00
Payout	0.00%	Debt/Eq	0.77	Sales Q/Q	-0.49%	SMA50	-21.28%	Rel Volume	2.37	Prev Close	161.35
Employees	20100	LT Debt/Eq	0.77	Earnings	Feb 18 BMO	SMA200	-6.46%	Avg Volume	818.82K	Price	158.53
IPO	Jun 23, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.95% 1.42%	Trades		Volume	1,936,969	Change	-1.75%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-15-25	Upgrade	BofA Securities	Neutral → Buy	$225
Nov-17-25	Upgrade	Argus	Hold → Buy
Nov-06-25	Upgrade	Robert W. Baird	Neutral → Outperform	$199
Oct-06-25	Upgrade	William Blair	Mkt Perform → Outperform
Oct-02-25	Upgrade	Barclays	Equal Weight → Overweight	$195
Sep-09-25	Upgrade	Jefferies	Hold → Buy	$195
Jul-09-25	Upgrade	Citigroup	Neutral → Buy	$200
May-23-25	Upgrade	Redburn Atlantic	Neutral → Buy	$182
May-14-25	Upgrade	TD Cowen	Hold → Buy	$179
May-08-25	Upgrade	Evercore ISI	In-line → Outperform	$170
Mar-21-25	Downgrade	Goldman	Buy → Neutral	$190 → $170
Mar-04-25	Upgrade	Citigroup	Sell → Neutral	$155 → $175
Mar-03-25	Upgrade	Redburn Atlantic	Sell → Neutral	$188
Jan-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Jan-17-25	Downgrade	UBS	Buy → Neutral	$250 → $185
Nov-18-24	Downgrade	CLSA	Hold → Underperform	$164
Nov-07-24	Upgrade	CLSA	Underperform → Hold	$205
Oct-23-24	Initiated	CLSA	Underperform	$167
Oct-14-24	Initiated	Redburn Atlantic	Sell
Oct-07-24	Downgrade	Evercore ISI	Outperform → In-line	$225 → $190

Show Previous Ratings

Today 07:01AM	Charles River Laboratories Announces Executive Appointments (Business Wire)
07:00AM	Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance (Business Wire)
Feb-16-26 10:05PM	Charles River Laboratories (CRL) Q4 Earnings: What To Expect (StockStory)
09:15AM	What Analyst Projections for Key Metrics Reveal About Charles River (CRL) Q4 Earnings (Zacks)
Feb-15-26 08:58AM	Analysts Are Bullish On Charles River Laboratories (CRL) Prospects (Insider Monkey)
09:39AM	Loading…
Feb-13-26 09:39AM	Here's How Charles River Stock Is Placed Ahead of Q4 Earnings (Zacks)
07:01AM	Mariner selects State Streets Charles River wealth platform (Private Banker International)
Feb-12-26 02:27PM	Mariner Has Big Growth Plans. State Streets Charles River Is Supplying the Tech Platform. (Barrons.com)
Feb-11-26 08:21PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research) -8.42%
10:00AM	Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-10-26 11:34PM	1 S&P 500 Stock with Competitive Advantages and 2 We Ignore (StockStory)
Feb-08-26 11:01PM	Charles River Laboratories (CRL): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Feb-02-26 07:15AM	Revvity (RVTY) Q4 Earnings and Revenues Beat Estimates (Zacks)
Jan-27-26 08:10AM	HCA Healthcare (HCA) Beats Q4 Earnings Estimates (Zacks)
Jan-21-26 04:30PM	Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call (Business Wire)
08:00AM	Loading…
08:00AM	Charles River Enters Manufacturing Collaboration with Gazi University (Business Wire)
Jan-20-26 11:04AM	Organon Secures FDA Approval Extending NEXPLANON Use to Five Years (Zacks)
11:00AM	Here's Why You Should Retain CLOV Stock in Your Portfolio for Now (Zacks)
Jan-19-26 05:59AM	What to Expect From Charles River Laboratories Next Quarterly Earnings Report (Barchart)
Jan-15-26 12:00PM	Here's Why Charles River Laboratories (CRL) is a Great Momentum Stock to Buy (Zacks)
09:42AM	Phibro Animal Health Stock Climbs 90.9% in a Year: What's Driving It? (Zacks)
Jan-12-26 04:30PM	Charles River Laboratories Provides Business Updates (Business Wire)
08:57AM	RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models (Zacks)
Jan-09-26 07:45AM	Tempus AI Stock Surges 82.4% in a Year: What's Driving It? (Zacks)
Jan-08-26 08:00AM	Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan (Business Wire)
Jan-06-26 12:00PM	What Makes Charles River (CRL) a New Buy Stock (Zacks)
09:15AM	Charles River Laboratories International, Inc. (CRL) Hit a 52 Week High, Can the Run Continue? (Zacks)
Dec-22-25 03:00PM	Why Charles River Laboratories (CRL) Stock Is Trading Up Today (StockStory)
Dec-18-25 08:36AM	Should You Continue to Hold CRL Stock in Your Portfolio for Now? (Zacks)
Dec-16-25 05:24AM	Is Charles River Laboratories Stock Underperforming the Dow? (Barchart)
04:36PM	Loading…
Dec-15-25 04:36PM	Stocks Fall Ahead of US November Payroll Report (Barchart)
Dec-11-25 08:00AM	Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort (Business Wire)
Dec-03-25 04:55PM	Charles River Laboratories (CRL) Shares Skyrocket, What You Need To Know (StockStory) +5.67%
Dec-01-25 03:42PM	HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Nov-24-25 07:56AM	What Makes Charles River Laboratories (CRL) an Investment Bet? (Insider Monkey)
Nov-21-25 03:24AM	Charles River Laboratories Stock: Is Wall Street Bullish or Bearish? (Barchart)
Nov-20-25 11:54AM	MA life sciences company Charles River Laboratories to lay off dozens of workers in 2026 (Worcester Telegram & Gazette)
Nov-17-25 09:15AM	Charles River (CRL) International Revenue Performance Explored (Zacks)
08:00AM	Charles River Laboratories to Present at Jefferies Global Healthcare Conference (Business Wire)
Nov-16-25 10:37PM	Drug Development Inputs & Services Stocks Q3 Teardown: Charles River Laboratories (NYSE:CRL) Vs The Rest (StockStory)
Nov-12-25 12:32AM	5 Must-Read Analyst Questions From Charles River Laboratories's Q3 Earnings Call (StockStory)
Nov-06-25 03:58PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
12:31AM	CRL Q3 Deep Dive: Portfolio Streamlining and End Market Stabilization Shape Outlook (StockStory)
Nov-05-25 08:15PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research) -5.71%
04:03PM	Charles River Laboratories International Inc (CRL) Q3 2025 Earnings Call Highlights: Strategic ... (GuruFocus.com)
12:26PM	Why Charles River Laboratories (CRL) Shares Are Getting Obliterated Today (StockStory)
09:30AM	Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
09:22AM	CRL's Q3 Earnings Top Estimates, Revenues Decline Y/Y, Stock Falls (Zacks)
08:10AM	Charles River Laboratories (CRL) Q3 Earnings and Revenues Surpass Estimates (Zacks)
07:51AM	Charles River Laboratories's (NYSE:CRL) Q3: Beats On Revenue (StockStory)
07:22AM	Charles River: Q3 Earnings Snapshot (Associated Press Finance)
07:01AM	Charles River Laboratories Provides Update on Strategic Review (Business Wire)
07:00AM	Charles River Laboratories Announces Third-Quarter 2025 Results (Business Wire)
Nov-03-25 10:12PM	What To Expect From Charles River Laboratories's (CRL) Q3 Earnings (StockStory)
Oct-30-25 10:00AM	Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-29-25 10:00AM	Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-27-25 07:17PM	HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Oct-24-25 10:22AM	Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
08:53AM	Here's How Charles River Stock Is Placed Ahead of Q3 Earnings (Zacks)
Oct-23-25 07:15AM	What to Expect From Charles River Laboratories' Q3 2025 Earnings Report (Barchart)
Oct-22-25 08:00AM	Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development (Business Wire)
Oct-20-25 07:22PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
12:10PM	Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:00AM	Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities (Business Wire)
Oct-15-25 08:00AM	Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoption (Business Wire)
Oct-14-25 08:00AM	Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call (Business Wire)
12:02AM	3 Reasons to Avoid CRL and 1 Stock to Buy Instead (StockStory)
Oct-10-25 11:50AM	3 Medical Service Industry Stocks Poised to Counter Workforce Issues (Zacks)
Oct-08-25 11:34PM	Winners And Losers Of Q2: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory)
08:00AM	Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing (Business Wire)
Oct-06-25 09:15AM	Pediatrix Medical Group, Inc. (MD) Soars to 52-Week High, Time to Cash Out? (Zacks)
Oct-04-25 08:31AM	Charles River price target raised to $200 from $190 at Evercore ISI (TipRanks)
Oct-03-25 04:16PM	S&P 500 Stocks: These 5 Lead As Index Hits Record High (Investor's Business Daily)
01:05PM	Charles River Laboratories (CRL) Stock Is Up, What You Need To Know (StockStory)
Oct-02-25 11:36AM	Why Charles River Laboratories (CRL) Stock Is Up Today (StockStory)
09:40AM	Nike upgraded, RH downgraded: Wall Street's top analyst calls (The Fly)
09:34AM	Life science tools Q3 preview: Barclays ups Charles River, downgrades Medpace (Investing.com)
Sep-24-25 01:59AM	Is Charles River Laboratories Stock Underperforming the Nasdaq? (Barchart)
Sep-18-25 07:31PM	Mr Wonderful Kevin O'Leary Says Bitcoin, Ethereum Enough To 'Capture The Promise' Of Crypto, Advises Against 'Irrelevant' Tokens (Benzinga)
Sep-17-25 08:27AM	Here's Why ClearBridge Investments Growth Strategy Closed Out Charles River Laboratories International (CRL) (Insider Monkey)
Sep-16-25 07:36AM	Insulet names new CFO; Dexcom CEO on leave (MedTech Dive)
07:05AM	Charles River Laboratories Announces Chief Financial Officer Transition (Business Wire)
Sep-12-25 08:44AM	CRL Stock Rises Following New Strategic Oncology Collaborations (Zacks)
Sep-11-25 08:00AM	Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer (Business Wire)
12:35AM	3 Unpopular Stocks That Concern Us (StockStory)
Sep-09-25 12:11PM	Jefferies backs IQVIA and Charles River, cuts ICON on customer losses (Investing.com)
09:35AM	Lululemon downgraded, Dick's Sporting upgraded: Wall Street's top analyst calls (The Fly)
Sep-08-25 08:00AM	Charles River Laboratories to Present at Baird and Morgan Stanley Conferences (Business Wire)
Sep-04-25 08:50AM	Is it the Right Time to Add CRL Stock to Your Portfolio Now? (Zacks)
Sep-03-25 08:00AM	Charles River Enhances Cell Therapy Flex Platform through Collaboration with Akadeum Life Sciences (Business Wire)
Sep-02-25 11:24AM	Danaher Gains From Business Strength Amid Persisting Headwinds (Zacks)
Sep-01-25 02:18PM	Podcast: Alternative testing models to shape toxicology with time (Clinical Trials Arena)
10:21AM	Charles River Stock May Benefit From Joining EASYGEN Consortium (Zacks)
Aug-27-25 10:23AM	Charles River Laboratories Stock: Analyst Estimates & Ratings (Barchart)
Aug-26-25 08:00AM	Charles River Joins EASYGEN Consortium, Supports Development of Bedside CAR-T Manufacturing (Business Wire)
Aug-20-25 07:45AM	Factbox-Healthcare firms see growing activist investor involvement in the past year (Reuters)
Aug-18-25 07:32PM	Biotechnology company shrinks Memphis expansion plans by 500+ jobs: Here's what we know (The Commercial Appeal)
Aug-13-25 01:36AM	5 Revealing Analyst Questions From Charles River Laboratories's Q2 Earnings Call (StockStory)
Aug-12-25 03:36PM	Cambodian Monkey, Destined for Research, Dies During Transport to Canada (GlobeNewswire)
03:13AM	CRL Q2 Deep Dive: Flat Sales and Margin Pressures Offset by Demand Stabilization and Raised Outlook (StockStory)

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The Discovery and Safety Assessment segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LaPlume Joseph W	EVP, Corp Strategy & Develop	Aug 22 '25	Sale	163.72	400	65,488	23,716	Jan 20 08:49 AM
Joseph LaPlume	Officer	Aug 22 '25	Proposed Sale	152.50	400	61,000		Aug 22 01:37 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Aug 18 '25	Sale	157.60	800	126,080	24,116	Aug 20 04:45 PM
WALLMAN RICHARD F	Former Director	Aug 18 '25	Proposed Sale	152.00	22,500	3,420,000		Aug 18 05:16 PM
Joseph LaPlume	Officer	Aug 18 '25	Proposed Sale	157.00	800	125,600		Aug 18 01:27 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Aug 07 '25	Sale	150.04	400	60,016	24,916	Aug 08 04:18 PM
Joseph LaPlume	Officer	Aug 07 '25	Proposed Sale	150.00	400	60,000		Aug 07 02:57 PM
WALLMAN RICHARD F	Former Director	Jul 21 '25	Proposed Sale	150.00	8,500	1,275,000		Jul 21 04:21 PM
WALLMAN RICHARD F	Former Director	Jun 23 '25	Proposed Sale	137.50	4,000	550,000		Jun 25 04:34 PM
MASSARO GEORGE	Director	May 15 '25	Sale	137.57	140	19,260	5,575	May 16 04:29 PM
MASSARO GEORGE	Director	May 14 '25	Sale	140.73	140	19,703	5,715	May 15 04:41 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	May 13 '25	Sale	145.41	500	72,705	19,513	May 15 04:38 PM
MASSARO GEORGE	Director	May 14 '25	Proposed Sale	140.73	280	39,405		May 14 04:05 PM
Joseph LaPlume	Officer	May 13 '25	Proposed Sale	144.32	500	72,160		May 13 03:33 PM
FOSTER JAMES C	Chairman, President and CEO	Feb 20 '25	Buy	165.01	6,075	1,002,436	183,639	Feb 21 04:41 PM
Girshick Birgit	Corporate Executive VP & COO	Feb 20 '25	Buy	164.63	1,514	249,250	55,058	Feb 21 04:38 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Feb 20 '25	Sale	162.50	4,400	715,000	20,013	Feb 21 04:36 PM
Joseph LaPlume	Officer	Feb 20 '25	Proposed Sale	165.00	4,400	726,000		Feb 20 12:36 PM

Open in Screener

OABI

OmniAb Inc

Feb 17 • 04:00PM ET

1.71

+0.01 0.59 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ONC EBS FOLD KURA MGNX ADAP XBIT ONCT

| Held by: VTI IWM VXF IBB IWN SCHA VTWO IWC VHT DFAS

Index	RUT	P/E	-	EPS (ttm)	-0.59	Insider Own	24.25%	Shs Outstand	143.96M	Perf Week	-4.47%
Market Cap	246.16M	Forward P/E	-	EPS next Y	-0.39	Insider Trans	-0.01%	Shs Float	109.04M	Perf Month	-10.94%
Enterprise Value	207.73M	PEG	-	EPS next Q	-0.09	Inst Own	42.40%	Short Float	5.35%	Perf Quarter	12.50%
Income	-63.67M	P/S	11.67	EPS this Y	11.27%	Inst Trans	8.43%	Short Ratio	12.32	Perf Half Y	-14.93%
Sales	21.09M	P/B	0.89	EPS next Y	27.69%	ROA	-19.86%	Short Interest	5.84M	Perf YTD	-7.57%
Book/sh	1.93	P/C	4.14	EPS next 5Y	23.56%	ROE	-22.37%	52W High	4.02 -57.46%	Perf Year	-55.12%
Cash/sh	0.41	P/FCF	-	EPS past 3/5Y	-22.79% -	ROIC	-21.61%	52W Low	1.22 40.16%	Perf 3Y	-53.53%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.76% -	Gross Margin	8.77%	Volatility	7.25% 6.76%	Perf 5Y	-
Dividend TTM	-	EV/Sales	9.85	EPS Y/Y TTM	5.16%	Oper. Margin	-321.85%	ATR (14)	0.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.00	Sales Y/Y TTM	3.36%	Profit Margin	-301.83%	RSI (14)	40.57	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.00	EPS Q/Q	9.94%	SMA20	-5.89%	Beta	0.16	Target Price	7.33
Payout	-	Debt/Eq	0.08	Sales Q/Q	-46.33%	SMA50	-10.09%	Rel Volume	0.66	Prev Close	1.70
Employees	114	LT Debt/Eq	0.06	Earnings	Nov 04 AMC	SMA200	-1.88%	Avg Volume	473.68K	Price	1.71
IPO	Sep 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.67% -48.98%	Trades		Volume	329,634	Change	0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$6
Apr-21-23	Initiated	The Benchmark Company	Buy	$8
Apr-13-23	Initiated	Craig Hallum	Buy	$10
Feb-22-23	Initiated	Cowen	Outperform	$10
Feb-13-23	Initiated	H.C. Wainwright	Buy	$11
Dec-20-22	Initiated	Truist	Buy	$10
Dec-16-22	Initiated	Credit Suisse	Outperform	$13
Nov-29-22	Initiated	SVB Leerink	Outperform	$6
Nov-28-22	Initiated	Stifel	Buy	$12

Dec-15-25 04:05PM	Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies (Business Wire) -5.58%
Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire) +8.00%
Dec-04-25 04:05PM	OmniAb to Hold OmniUltra Virtual Investor Event on December 15 (Business Wire)
Nov-17-25 05:23PM	OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors (Business Wire) +5.92%
Nov-05-25 12:06AM	OmniAb Inc (OABI) Q3 2025 Earnings Call Highlights: Strong Program Momentum Amid Revenue Decline (GuruFocus.com)
06:35PM	Loading…
Nov-04-25 06:35PM	OmniAb, Inc. (OABI) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights (Business Wire)
Nov-03-25 08:07AM	What To Expect From OmniAb Inc (OABI) Q3 2025 Earnings (GuruFocus.com)
Oct-30-25 10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 10:00AM	OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-16-25 08:55AM	Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains? (Zacks)
08:00AM	OmniAb to Participate in Three Investor Conferences in November (Business Wire)
Oct-14-25 08:00AM	OmniAb to Report Third Quarter 2025 Financial Results on November 4 (Business Wire)
Sep-02-25 08:00AM	OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-25-25 07:00AM	OmniAb Announces $30 Million Private Placement (Business Wire) -11.89%
06:15PM	Loading…
Aug-06-25 06:15PM	OmniAb, Inc. (OABI) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.39%
04:05PM	OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Aug-05-25 10:26AM	OmniAb Inc (OABI) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Jul-16-25 08:00AM	OmniAb to Report Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jun-30-25 09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
May-13-25 04:05PM	OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration Platform at the 21st Annual PEGS Boston Summit (Business Wire) +8.57%
May-09-25 08:31AM	Is OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey) -8.28%
May-08-25 05:40PM	OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:06PM	OmniAb Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
04:05PM	OmniAb Introduces the xPloration® Partner Access Program (Business Wire)
May-05-25 12:59PM	VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program (GlobeNewswire)
May-01-25 08:00AM	OmniAb to Participate in Five Upcoming Investor Conferences (Business Wire)
Apr-21-25 08:00AM	OmniAb Announces Two New Appointments to its Board of Directors (Business Wire)
Apr-14-25 08:00AM	OmniAb to Report First Quarter 2025 Financial Results on May 8 (Business Wire)
Mar-18-25 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (Business Wire) -20.38%
08:00AM	Loading…
Feb-24-25 08:00AM	OmniAb to Report Fourth Quarter 2024 Financial Results on March 18 (Business Wire)
Feb-03-25 04:57PM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-16-24 04:15PM	OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering and Therapeutics Conference (Business Wire)
Nov-12-24 04:05PM	OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire) -9.35%
Oct-30-24 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Oct-22-24 08:00AM	OmniAb to Report Third Quarter 2024 Financial Results on November 12 (Business Wire)
Aug-26-24 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-08-24 04:05PM	OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.67%
Jul-25-24 08:00AM	OmniAb to Report Second Quarter 2024 Financial Results on August 8 (Business Wire)
Jun-03-24 04:05PM	OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology (Business Wire)
May-20-24 08:05AM	OmniAb to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-15-24 04:05PM	OmniAb Presents High-Throughput Single B-cell Screening xPloration Data at the 20th Annual PEGS Boston Summit (Business Wire)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-09-24 08:56PM	OABI Stock Earnings: OmniAb Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	OmniAb Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
May-01-24 08:00AM	OmniAb to Participate in Five Investor Conferences in May (Business Wire)
Apr-22-24 08:00AM	OmniAb to Report First Quarter 2024 Financial Results on May 9 (Business Wire)
Mar-21-24 11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.17%
Mar-20-24 08:54PM	OABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Feb-28-24 08:27AM	OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-24 08:00AM	OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 (Business Wire)
Feb-20-24 08:00AM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-14-23 04:30PM	OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference (Business Wire)
Nov-20-23 12:39PM	OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 05:03AM	Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares (GuruFocus.com) +6.32%
Nov-09-23 05:55PM	OmniAb Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at Todays Research & Technology Virtual Event (Business Wire)
09:24AM	OmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net Loss (GuruFocus.com)
08:00AM	OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Nov-02-23 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Nov-01-23 09:00AM	OmniAb Appoints Steve Love to its Board of Directors (Business Wire)
Oct-31-23 04:28PM	OmniAb Announces Agenda for its Research & Technology Virtual Event (Business Wire)
Oct-26-23 02:32PM	7 of the Best Cheap Stocks to Buy Under $5 in October 2023 (InvestorPlace)
Oct-12-23 08:00AM	OmniAb to Hold Research & Technology Virtual Event on November 9 (Business Wire)
Sep-05-23 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-15-23 05:20AM	OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-13-23 08:06AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-10-23 04:05PM	OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire) -5.54%
Aug-07-23 04:05PM	OmniAb Announces the Passing of Director Sunil Patel (Business Wire)
Jul-31-23 08:00AM	OmniAb to Report Second Quarter 2023 Financial Results on August 10 (Business Wire)
Jul-17-23 07:35AM	With 60% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big guns (Simply Wall St.)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +6.32%
May-18-23 05:09PM	7 Stocks to Buy for Their Massive Upside Potential (InvestorPlace)
May-17-23 04:05PM	OmniAb Launches OmniDeep at the PEGS Boston Conference and Expo (Business Wire)
May-16-23 06:06AM	President of OmniAb Matthew Foehr Buys 22% More Shares \ (Simply Wall St.) +9.12%
May-14-23 08:03AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 10:55PM	Q1 2023 OmniAb Inc Earnings Call (Thomson Reuters StreetEvents) +8.36%
07:00AM	OmniAb Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-05-23 07:14AM	OmniAb, Inc.'s (NASDAQ:OABI) Share Price Matching Investor Opinion (Simply Wall St.)
May-04-23 06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
May-01-23 08:00AM	OmniAb to Report First Quarter 2023 Financial Results on May 11 (Business Wire)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-25-23 08:00AM	OmniAb to Participate in Upcoming Investor Conferences in May (Business Wire)
Apr-19-23 08:30AM	Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today (Zacks)
Apr-07-23 10:24PM	OmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-05-23 06:09AM	OmniAb Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Apr-02-23 08:51AM	Insiders of OmniAb, Inc. (NASDAQ:OABI) are up 11% on their US$2.3m purchase after OmniAb, Inc. (NASDAQ:OABI) rose 14% last week (Simply Wall St.)
Mar-31-23 08:40AM	Do Options Traders Know Something About OmniAb (OABI) Stock We Don't? (Zacks)
Mar-30-23 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Business Wire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-09-23 08:00AM	OmniAb to Report Fourth Quarter 2022 Financial Results on March 30 (Business Wire) -5.03%
Mar-08-23 09:53AM	These 2 Strong Buy Penny Stocks Are Poised for a Massive Rally, Say Analysts (TipRanks)
Feb-23-23 07:49AM	Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up (Zacks)
Feb-07-23 08:00AM	OmniAb to Participate in Three Upcoming Investor Conferences (Business Wire)
Feb-01-23 06:56AM	With 44% stake, OmniAb, Inc. (NASDAQ:OABI) seems to have captured institutional investors' interest (Simply Wall St.)
Dec-16-22 12:39PM	Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says (Benzinga)
Dec-01-22 08:47AM	Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies (HSB-1940) against PD-1, by combining Quatramers with OmniAbs Picobodies, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets (GlobeNewswire) -5.37%
Nov-15-22 07:00AM	OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights (Business Wire) -10.00%
Nov-03-22 08:00AM	OmniAb to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-02-22 07:00AM	OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell (Business Wire) -60.65%

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FOEHR MATTHEW W	President and CEO	Feb 16 '26	Option Exercise	0.00	36,458	0	4,396,541	Feb 17 06:22 PM
FOEHR MATTHEW W	President and CEO	Feb 17 '26	Sale	1.70	20,754	35,282	4,375,787	Feb 17 06:22 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 16 '26	Option Exercise	0.00	13,542	0	266,230	Feb 17 06:20 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 17 '26	Sale	1.70	6,828	11,608	259,402	Feb 17 06:20 PM
Berkman Charles S	Chief Legal Officer	Feb 16 '26	Option Exercise	0.00	13,542	0	390,613	Feb 17 06:18 PM
Berkman Charles S	Chief Legal Officer	Feb 17 '26	Sale	1.70	6,990	11,883	383,623	Feb 17 06:18 PM
FOEHR MATTHEW W	Officer	Feb 17 '26	Proposed Sale	1.70	20,483	34,821		Feb 17 04:33 PM
Berkman Charles S	Officer	Feb 17 '26	Proposed Sale	1.70	6,891	11,715		Feb 17 04:29 PM
GUSTAFSON KURT A	Officer	Feb 17 '26	Proposed Sale	1.70	6,891	11,715		Feb 17 04:27 PM
Berkman Charles S	Chief Legal Officer	Dec 07 '25	Option Exercise	0.00	15,621	0	385,115	Dec 09 09:02 AM
Berkman Charles S	Chief Legal Officer	Dec 08 '25	Sale	1.96	8,044	15,766	377,071	Dec 09 09:02 AM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 07 '25	Option Exercise	0.00	46,500	0	276,610	Dec 09 09:02 AM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 08 '25	Sale	1.96	23,922	46,887	252,688	Dec 09 09:02 AM
FOEHR MATTHEW W	President and CEO	Dec 07 '25	Option Exercise	0.00	26,554	0	4,373,749	Dec 09 09:01 AM
FOEHR MATTHEW W	President and CEO	Dec 08 '25	Sale	1.96	13,666	26,785	4,360,083	Dec 09 09:01 AM
GUSTAFSON KURT A	Officer	Dec 08 '25	Proposed Sale	1.96	23,922	46,910		Dec 08 07:17 PM
FOEHR MATTHEW W	Officer	Dec 08 '25	Proposed Sale	1.96	13,666	26,798		Dec 08 07:15 PM
Berkman Charles S	Officer	Dec 08 '25	Proposed Sale	1.96	8,044	15,774		Dec 08 07:14 PM
HIGGINS JOHN L	Director	Nov 07 '25	Buy	1.38	41,038	56,632	2,929,148	Nov 10 08:30 AM
HIGGINS JOHN L	Director	Nov 06 '25	Buy	1.41	36,223	51,074	2,888,110	Nov 10 08:30 AM
Cochran Jennifer R.	Director	May 15 '25	Buy	1.52	30,000	45,600	145,274	May 15 04:02 PM
Love Steven	Director	May 14 '25	Buy	1.46	25,000	36,500	38,333	May 14 05:04 PM
HIGGINS JOHN L	Director	May 12 '25	Buy	1.44	65,000	93,600	2,831,887	May 13 05:52 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Option Exercise	0.00	36,458	0	3,815,618	Apr 07 08:17 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Sale	2.00	19,382	38,764	3,796,236	Apr 07 08:17 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Option Exercise	0.00	13,542	0	370,418	Apr 07 08:10 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Sale	2.00	7,206	14,412	363,212	Apr 07 08:10 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Option Exercise	0.00	13,542	0	231,034	Apr 07 08:09 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Sale	2.00	7,206	14,412	223,828	Apr 07 08:09 PM
GUSTAFSON KURT A	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 08:04 PM
FOEHR MATTHEW W	Officer	Apr 07 '25	Proposed Sale	2.00	19,382	38,715		Apr 07 08:00 PM
Berkman Charles S	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 07:56 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Option Exercise	0.00	23,244	0	229,455	Apr 01 08:43 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Sale	2.37	11,963	28,352	217,492	Apr 01 08:43 PM
GUSTAFSON KURT A	Officer	Apr 01 '25	Proposed Sale	2.37	11,963	28,351		Apr 01 07:16 PM
HIGGINS JOHN L	Director	Mar 21 '25	Buy	2.28	4,000	9,120	2,766,887	Mar 21 07:58 PM
HIGGINS JOHN L	Director	Mar 20 '25	Buy	2.35	125,750	295,512	2,762,887	Mar 20 08:15 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 19 '25	Sale	3.67	7,255	26,626	206,211	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 19 '25	Sale	3.67	19,522	71,646	3,779,160	Feb 19 08:51 PM
Berkman Charles S	Chief Legal Officer	Feb 19 '25	Sale	3.67	7,255	26,626	356,876	Feb 19 08:50 PM
GUSTAFSON KURT A	Officer	Feb 19 '25	Proposed Sale	3.68	5,188	19,092		Feb 18 08:36 PM

Open in Screener

NRC

National Research Corp

Feb 17 • 04:00PM ET

12.03

-0.05 -0.41 %

Healthcare • Health Information Services • USA • NASD

NRC National Research Corp daily Stock Chart

Peers: STAA EHC ACHC SMLR MD SGRY HCSG HQY ENSV SGRP

| Held by: VTI IWM VXF DES IWO VTWO SCHA DFAS SMLF DGRS

Index	RUT	P/E	23.76	EPS (ttm)	0.51	Insider Own	43.10%	Shs Outstand	22.64M	Perf Week	-21.73%
Market Cap	272.57M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	12.89M	Perf Month	-43.52%
Enterprise Value	347.46M	PEG	-	EPS next Q	-	Inst Own	48.11%	Short Float	2.74%	Perf Quarter	-22.59%
Income	11.39M	P/S	1.98	EPS this Y	-	Inst Trans	-1.83%	Short Ratio	3.61	Perf Half Y	-21.42%
Sales	137.39M	P/B	19.47	EPS next Y	-	ROA	8.31%	Short Interest	0.35M	Perf YTD	-35.91%
Book/sh	0.62	P/C	65.84	EPS next 5Y	-	ROE	50.31%	52W High	22.79 -47.21%	Perf Year	-32.03%
Cash/sh	0.18	P/FCF	17.32	EPS past 3/5Y	-25.81% -18.58%	ROIC	12.79%	52W Low	9.76 23.32%	Perf 3Y	-73.79%
Dividend Est.	-	EV/EBITDA	11.50	Sales past 3/5Y	-3.22% 0.61%	Gross Margin	56.33%	Volatility	10.08% 8.32%	Perf 5Y	-74.13%
Dividend TTM	0.52 (4.32%)	EV/Sales	2.53	EPS Y/Y TTM	-51.57%	Oper. Margin	16.44%	ATR (14)	1.28	Perf 10Y	-14.33%
Dividend Ex-Date	Mar 27, 2026	Quick Ratio	0.53	Sales Y/Y TTM	-3.96%	Profit Margin	8.29%	RSI (14)	24.63	Recom	3.00
Dividend Gr. 3/5Y	-14.77% 19.88%	Current Ratio	0.55	EPS Q/Q	-70.66%	SMA20	-32.43%	Beta	0.57	Target Price	44.00
Payout	100.39%	Debt/Eq	5.65	Sales Q/Q	-4.64%	SMA50	-34.40%	Rel Volume	1.38	Prev Close	12.08
Employees	368	LT Debt/Eq	5.36	Earnings	Feb 03 BMO	SMA200	-22.44%	Avg Volume	97.85K	Price	12.03
IPO	May 23, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	134,323	Change	-0.41%

Feb-09-26 12:50PM	NRC's Q4 Earnings Down Y/Y on High Client Attrition, Stock Falls 27% (Zacks)
Feb-04-26 08:00AM	NRC Health Named #1 Best in KLAS Again for Healthcare Experience Management (Business Wire) -13.34%
Feb-03-26 08:08PM	National Research Q4 Earnings Call Highlights (MarketBeat) -19.54%
09:00AM	NRC Health Announces Fourth Quarter 2025 Results (Business Wire)
Feb-02-26 06:35AM	The Zacks Analyst Blog Highlights Meta Platforms, Palantir Technologies, Amphenol and National Research (Zacks) +7.67%
04:03AM	Loading…
Jan-30-26 04:03AM	National Research Says Pairing NPS With HCAHPS Can Boost Patient Experienceand Reimbursement (MarketBeat)
Dec-02-25 09:00AM	NRC Health Partners with Mosaic Life Care to Advance Patient Experience Across the Midwest (Business Wire)
Nov-20-25 09:00AM	NRC Health Appoints David Burik as Executive Vice President, Strategic Insights (Business Wire)
Nov-13-25 09:00AM	NRC Health Partners with BJC HealthCare to Advance Experience Excellence Across a Unified Network (Business Wire)
Oct-31-25 01:53PM	NRC Stock Up 12% Despite Q3 Earnings Down Y/Y on Rising Interest Costs (Zacks)
Oct-30-25 03:21PM	National Research Corp (NRC) Q3 2025 Earnings Call Highlights: Strong TRCV Growth and Strategic ... (GuruFocus.com)
Oct-27-25 05:00PM	NRC Health Announces Third Quarter 2025 Results (Business Wire) +16.02%
Oct-15-25 09:40AM	Mercy Earns National Honor for Excellence in Patient Experience (PR Newswire)
06:45AM	NRC Health Honors 2025 Leaders in Patient Experience and Loyalty (Business Wire)
Sep-11-25 08:34AM	NRC Health Welcomes South Shore Health to Advance Patient and Employee Experience (Business Wire)
08:00AM	Loading…
Aug-28-25 08:00AM	NRC Health Announces Shane Harrison as Chief Financial Officer (Business Wire) -5.36%
Aug-01-25 01:53PM	NRC's Q2 Earnings Rise Y/Y on Cost Control and TRCV Growth (Zacks)
Jul-30-25 03:12AM	National Research Corp (NRC) Q2 2025 Earnings Call Highlights: Strong Growth Amid Leadership ... (GuruFocus.com)
Jul-28-25 05:07PM	National Research: Q2 Earnings Snapshot (Associated Press Finance)
05:00PM	NRC Health Announces Second Quarter 2025 Results (Business Wire)
Jun-26-25 02:16AM	National Research Solidifies Dividend Amid Insider Buying and Contract Growth (Insider Monkey)
May-02-25 01:13PM	NRC Q1 Earnings Dip Y/Y Amid Rising Interest Costs, Shares Up 13% (Zacks) +5.41%
Apr-28-25 05:00PM	NRC Health Announces First Quarter Results (Business Wire) +9.50%
Apr-10-25 02:01PM	A New Era of Trust: NRC Healths 2025 Experience Perspective Report Reveals Insights to Elevate the Healthcare Experience (Business Wire) -10.78%
Mar-24-25 05:00PM	National Research Corporation Declares Quarterly Dividend (Business Wire) -6.57%
07:23AM	The Zacks Analyst Blog Philip Morris, Booking Holdings, Anheuser-Busch InBev, Elite Pharmaceuticals and National Research (Zacks)
Mar-21-25 06:18PM	Top Stock Reports for Philip Morris, Booking Holdings & Anheuser-Busch (Zacks)
Mar-04-25 04:01PM	National Research Corporation Appoints Trent Green as Chief Executive Officer (Business Wire)
Feb-25-25 08:03AM	UofL Health Chooses NRC Health to Elevate Patient and Employee Experience Initiatives (Business Wire)
Feb-11-25 09:01AM	NRC Health Partners with UC Health to Enhance Healthcare Consumer Experience (Business Wire)
08:01AM	Loading…
Feb-05-25 08:01AM	NRC Health ranked #1 Best in KLAS for Healthcare Experience Management (Business Wire)
Jan-27-25 05:00PM	National Research Corporation Announces Fourth Quarter Results (Business Wire) -11.85%
Jan-07-25 12:00PM	Renown Health selects NRC Health as partner to enhance patient experience and operational efficiency (Business Wire)
Nov-20-24 09:02AM	Signature Healthcare Elevates Patient Experience and Workforce Engagement Through Strategic Partnership With NRC Health (Business Wire)
Nov-12-24 09:02AM	Cooper University Health Care Selects NRC Health as New Patient Experience Partner (Business Wire)
Oct-25-24 05:00PM	National Research Corporation Announces Third Quarter Results (Business Wire)
Aug-22-24 01:00PM	AI meets empathy: NRC Health launches first AI-enabled solutions to elevate healthcare experience (Business Wire)
Aug-06-24 05:00PM	National Research Corporation Announces Second Quarter Results (Business Wire) -9.54%
May-07-24 05:00PM	National Research Corporation Announces First Quarter Results (Business Wire) -16.47%
Apr-18-24 04:23PM	National Research Corporation to Broadcast Its First Quarter 2024 Conference Call Live on the Internet (Business Wire)
Apr-02-24 11:55AM	Veteran Patient Experience Executive Jennifer Baron Joins NRC Health as Its First Chief Experience Officer (Business Wire) -7.02%
Feb-13-24 05:33PM	National Research Corp (NRC) Reports Q4 and Full-Year 2023 Financial Results (GuruFocus.com) +6.13%
05:00PM	National Research Corporation Announces Fourth Quarter and Calendar Year 2023 Results (Business Wire)
Feb-01-24 03:00PM	National Research Corporation to Broadcast Its Fourth Quarter and Year-end 2023 Conference Call Live on the Internet (Business Wire)
10:00AM	NRC Health Expands Leadership Team to Accelerate Innovation, Meet Growing Demand for Insights and Solutions (Business Wire)
Jan-31-24 10:00AM	Yuma Regional Medical Center Selects NRC Health as New Patient Experience Partner (Business Wire)
Jan-17-24 03:00PM	National Research Corporation Elevates Leadership Team to Seize Growth Opportunity (Business Wire)
Nov-17-23 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
Nov-09-23 02:08PM	National Research Corporation (NASDAQ:NRC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 05:00PM	National Research Corporation Announces Third Quarter 2023 Results (GlobeNewswire)
Oct-24-23 04:00PM	National Research Corporation to Broadcast its 2023 Third Quarter Conference Call Live on the Internet (GlobeNewswire)
Sep-26-23 08:55AM	Lurie Childrens expands partnership with NRC Health to gain valuable consumer insights (GlobeNewswire)
Sep-06-23 05:00PM	National Research Corporation Declares Special Dividend (GlobeNewswire)
Aug-31-23 06:55AM	NRC Health emphasizes its commitment to ICDs annual Patient Experience Symposium (GlobeNewswire)
Aug-29-23 08:55AM	LifeBridge Health selects NRC Health as its new patient experience partner (GlobeNewswire)
Aug-21-23 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
Aug-08-23 12:33PM	NRC Health unveils winners of 2023 patient experience and loyalty awards (GlobeNewswire)
Aug-01-23 05:00PM	National Research Corporation Announces Second Quarter 2023 Results (GlobeNewswire)
Jul-26-23 09:28AM	National Research (NASDAQ:NRC) Is Achieving High Returns On Its Capital (Simply Wall St.)
Jul-18-23 04:00PM	National Research Corporation to Broadcast its 2023 Second Quarter Conference Call Live on the Internet (GlobeNewswire)
Jul-12-23 11:51AM	Bryan Health Chooses NRC Health as Patient Experience Partner (GlobeNewswire)
May-31-23 12:50PM	NRC Health partners with ICD as lead sponsor of 7th Annual Patient Experience Symposium (GlobeNewswire)
May-25-23 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
May-12-23 02:16PM	UCHealth Partners with NRC Health to Improve Healthcare Experiences (GlobeNewswire)
May-02-23 05:00PM	National Research Corporation Announces First Quarter 2023 Results (GlobeNewswire) -7.63%
Apr-18-23 05:18PM	National Research Corporation to Broadcast its 2023 First Quarter Conference Call Live on the Internet (GlobeNewswire)
Apr-06-23 10:00AM	NRC Health reveals 2023 Pediatric Experience Perspective (GlobeNewswire)
Mar-30-23 10:00AM	NRC Health energizes healthcare organizations with digital solution to ease burnout for care teams (GlobeNewswire)
Mar-02-23 01:21PM	NRC Health offers first-of-its-kind patient experience EHR integration (GlobeNewswire)
Feb-15-23 01:00PM	Keys to delivering humanized care revealed in NRC Healths 2023 Experience Perspective (GlobeNewswire) +5.42%
Feb-14-23 05:00PM	National Research Corporation Announces Fourth Quarter and Calendar Year 2022 Results (GlobeNewswire)
Feb-08-23 08:01AM	NRC Health recognized as Best in KLAS for Patient Experience Improvement (GlobeNewswire)
Feb-03-23 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
Jan-30-23 03:34PM	National Research Corporation to Broadcast its 2022 Fourth Quarter Conference Call Live on the Internet (GlobeNewswire)
Nov-11-22 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire) -6.56%
Nov-09-22 05:12AM	National Research Third Quarter 2022 Earnings: EPS: US$0.34 (vs US$0.38 in 3Q 2021) (Simply Wall St.)
Nov-01-22 05:00PM	National Research Corporation Announces Third Quarter 2022 Results (GlobeNewswire) -13.16%
09:00AM	NRC Health Study Finds Trust in Local Hospitals and Health Systems Increased During the Pandemic (GlobeNewswire)
Oct-19-22 02:49PM	National Research Corporation to Broadcast its 2022 Third Quarter Conference Call Live on the Internet (GlobeNewswire)
Sep-29-22 09:00AM	NRC Health Announces Sponsorship of Creative Learning Event Series Hosted by the Society for Participatory Medicine (GlobeNewswire)
Aug-23-22 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
Aug-16-22 02:38PM	NRC Health Unveils Winners of 2022 Annual Awards Programs (GlobeNewswire)
Aug-12-22 11:16AM	NRC Health Announces Partnership with The Beryl Institute (GlobeNewswire)
Aug-02-22 05:00PM	National Research Corporation Announces Second Quarter 2022 Results (GlobeNewswire)
Jul-19-22 04:12PM	National Research Corporation to Broadcast its 2022 Second Quarter Conference Call Live on the Internet (GlobeNewswire)
Jul-11-22 08:03AM	National Research Corporation (NASDAQ:NRC) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? (Simply Wall St.)
Jun-30-22 09:00AM	CISOs Connect Names NRC Health Chief Security and Privacy Officer Among 2022 Top 100 CISOs in the Country (GlobeNewswire)
Jun-10-22 10:12AM	We Like National Research's (NASDAQ:NRC) Returns And Here's How They're Trending (Simply Wall St.)
May-23-22 10:07AM	We Think National Research (NASDAQ:NRC) Can Manage Its Debt With Ease (Simply Wall St.)
May-20-22 05:00PM	National Research Corporation Announces Quarterly Dividend and Stock Repurchase Authorization (GlobeNewswire)
May-19-22 09:00AM	National Research Corporation Announces Appointment to Board of Directors (GlobeNewswire)
May-04-22 08:42AM	National Research's (NASDAQ:NRC) five-year total shareholder returns outpace the underlying earnings growth (Simply Wall St.)
May-03-22 05:00PM	National Research Corporation Announces First Quarter 2022 Results (GlobeNewswire)
Apr-19-22 04:35PM	National Research Corporation to Broadcast its 2022 First Quarter Conference Call Live on the Internet (GlobeNewswire)
Mar-26-22 02:24PM	Is It Smart To Buy National Research Corporation (NASDAQ:NRC) Before It Goes Ex-Dividend? (Simply Wall St.)
Mar-16-22 10:21AM	Second Annual Report from NRC Health Highlights Major Trends in Pediatric Care (GlobeNewswire)
Mar-03-22 10:21AM	What Is The Ownership Structure Like For National Research Corporation (NASDAQ:NRC)? (Simply Wall St.)
Feb-14-22 05:00PM	NRC Health Declares Quarterly Dividend (GlobeNewswire) +5.30%
Feb-08-22 05:00PM	National Research Corporation Announces Fourth Quarter and Calendar Year 2021 Results (GlobeNewswire)
Feb-01-22 11:13AM	National Research Corporation (NASDAQ:NRC) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? (Simply Wall St.) -5.87%

National Research Corp. engages in the provision of analytics and insights that facilitate patient, employee, and customer retention. It offers solutions that address specific needs around market insight, experience, transparency, and governance for healthcare providers, payers, and other healthcare organizations. The company was founded by Michael D. Hays in 1981 and is headquartered in Lincoln, NE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hays Michael D.	Chairman	Jan 05 '26	Option Exercise	15.23	9,145	139,278	20,154	Jan 07 05:39 PM
Hrdy Helen	EVP & Chief Operating Officer	Dec 15 '25	Option Exercise	15.23	12,346	188,030	151,762	Dec 17 06:23 PM
Freeman Jordan Nicole	Chief Accounting Officer	Jul 31 '25	Buy	12.97	771	10,000	771	Aug 04 04:40 PM
BEANS PATRICK E	10% Owner	May 12 '25	Buy	13.59	2,500	33,974	35,003	May 13 11:30 AM

Open in Screener

MEDP

Medpace Holdings Inc

Feb 17 • 04:00PM ET

428.18

+0.15 0.04 %

Healthcare • Diagnostics & Research • USA • NASD

MEDP Medpace Holdings Inc daily Stock Chart

Peers: IQV CRL INCY LH ICON CTLT KOD FATE ALLO ONC

| Held by: VTI IJH VB VBK VXF XMHQ IBB MDY IWP COWG

Index	-	P/E	28.00	EPS (ttm)	15.29	Insider Own	19.54%	Shs Outstand	28.30M	Perf Week	-19.26%
Market Cap	12.15B	Forward P/E	22.44	EPS next Y	19.08	Insider Trans	-7.40%	Shs Float	22.83M	Perf Month	-30.72%
Enterprise Value	11.79B	PEG	1.79	EPS next Q	3.94	Inst Own	84.61%	Short Float	5.87%	Perf Quarter	-27.59%
Income	451.12M	P/S	4.80	EPS this Y	11.62%	Inst Trans	-3.77%	Short Ratio	4.48	Perf Half Y	-6.48%
Sales	2.53B	P/B	26.40	EPS next Y	11.85%	ROA	22.13%	Short Interest	1.34M	Perf YTD	-23.76%
Book/sh	16.22	P/C	24.45	EPS next 5Y	12.57%	ROE	70.23%	52W High	628.92 -31.92%	Perf Year	25.87%
Cash/sh	17.51	P/FCF	17.82	EPS past 3/5Y	28.02% 31.79%	ROIC	78.77%	52W Low	250.05 71.24%	Perf 3Y	107.39%
Dividend Est.	-	EV/EBITDA	20.94	Sales past 3/5Y	20.12% 22.27%	Gross Margin	28.95%	Volatility	6.83% 4.64%	Perf 5Y	158.78%
Dividend TTM	-	EV/Sales	4.66	EPS Y/Y TTM	19.83%	Oper. Margin	21.14%	ATR (14)	25.62	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.74	Sales Y/Y TTM	19.97%	Profit Margin	17.83%	RSI (14)	20.17	Recom	3.20
Dividend Gr. 3/5Y	- -	Current Ratio	0.74	EPS Q/Q	27.08%	SMA20	-21.21%	Beta	1.46	Target Price	505.18
Payout	0.00%	Debt/Eq	0.30	Sales Q/Q	32.03%	SMA50	-23.95%	Rel Volume	1.47	Prev Close	428.03
Employees	6200	LT Debt/Eq	0.25	Earnings	Feb 09 AMC	SMA200	-9.05%	Avg Volume	299.33K	Price	428.18
IPO	Aug 11, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.58% 2.78%	Trades		Volume	429,923	Change	0.04%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-13-26	Upgrade	Jefferies	Hold → Buy	$560
Feb-10-26	Upgrade	Robert W. Baird	Neutral → Outperform	$564
Nov-13-25	Initiated	BMO Capital Markets	Market Perform	$600
Oct-02-25	Downgrade	Barclays	Equal Weight → Underweight	$425
Sep-03-25	Downgrade	Rothschild & Co Redburn	Buy → Neutral	$474
Jul-29-25	Downgrade	UBS	Neutral → Sell	$305
Jul-23-25	Downgrade	TD Cowen	Hold → Sell	$366
Jun-24-25	Initiated	Barclays	Equal Weight	$300
Apr-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Apr-14-25	Downgrade	TD Cowen	Buy → Hold	$328
Mar-24-25	Initiated	Leerink Partners	Market Perform	$330
Oct-23-24	Downgrade	Robert W. Baird	Outperform → Neutral	$413 → $349
Oct-14-24	Initiated	Redburn Atlantic	Buy
Sep-27-24	Downgrade	UBS	Buy → Neutral	$420 → $350
Sep-25-24	Downgrade	Jefferies	Buy → Hold	$415 → $345
Aug-01-24	Initiated	Truist	Hold	$415
May-29-24	Initiated	TD Cowen	Buy	$452
May-28-24	Initiated	Mizuho	Buy	$435
Apr-23-24	Upgrade	Jefferies	Hold → Buy	$340 → $450
Mar-18-24	Initiated	Deutsche Bank	Hold	$395

Show Previous Ratings

Feb-16-26 12:31AM	The 5 Most Interesting Analyst Questions From Medpace's Q4 Earnings Call (StockStory)
Feb-15-26 08:32AM	Pinterest, DraftKings, And Flutter Are Among Top 10 Large Cap Losers Last Week (Feb. 9-Feb. 13): Are the Others in Your Portfolio? (Benzinga)
Feb-11-26 07:24PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research)
Feb-10-26 07:38PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research) -15.90%
04:09PM	The 'Key Negative' That Took Out Medpace's Sales, Profit Beat (Investor's Business Daily)
04:00PM	Loading…
04:00PM	Medpace Holdings Inc (MEDP) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
03:50PM	Medpace Q4 Earnings Call Highlights (MarketBeat)
01:11PM	Dow Jones Reaches Record Highs, Software Stocks Extend Rebound: What's Moving Markets Tuesday? (Benzinga)
10:35AM	MEDP Q4 Deep Dive: Cancellations and Metabolic Trial Mix Pressure Margins Despite Strong Growth (StockStory)
Feb-09-26 05:25PM	Medpace (MEDP) Beats Q4 Earnings and Revenue Estimates (Zacks)
04:31PM	Medpace (NASDAQ:MEDP) Reports Bullish Q4 CY2025 (StockStory)
04:21PM	Medpace: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results (Business Wire)
Feb-07-26 10:01PM	Earnings To Watch: Medpace (MEDP) Reports Q4 Results Tomorrow (StockStory)
Jan-30-26 06:15PM	Medpace (MEDP) Declines More Than Market: Some Information for Investors (Zacks)
09:06AM	Loading…
09:06AM	Here's Why Medpace (MEDP) Shares Roared in 2025 (Insider Monkey)
Jan-23-26 06:15PM	Medpace (MEDP) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
08:34AM	Vulcan Value Partners' Thoughts on Medpace Holdings (MEDP) (Insider Monkey)
Jan-17-26 11:37AM	S&P 500 Financial Titan BlackRock Leads Five Stocks To Watch (Investor's Business Daily)
Jan-16-26 12:19PM	Stock Market Today: Indexes Higher Amid Trump's Remarks On Next Fed Chair; Biotech Breaks Out (Live Coverage) (Investor's Business Daily)
Jan-15-26 11:02PM	Medpace (MEDP): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Jan-14-26 06:15PM	Why the Market Dipped But Medpace (MEDP) Gained Today (Zacks)
Jan-13-26 05:12PM	IBD Stock Of The Day Medpace Tests Early Buy Point As Biotech Funding Shines (Investor's Business Daily)
Jan-12-26 10:07AM	Zacks Industry Outlook Highlights Medpace, Enhabit and Progyny (Zacks)
09:56AM	GeneDx Partners With Komodo Health to Advance Rare Disease Research (Zacks)
Jan-09-26 10:53AM	SENS Stock Up as Eversense 365 Enters AID Market With twiist System (Zacks)
09:04AM	3 Medical Service Industry Stocks Set to Tackle Workforce Challenges (Zacks)
Jan-08-26 06:15PM	Medpace (MEDP) Stock Dips While Market Gains: Key Facts (Zacks)
08:29AM	Here's Why You Should Hold Avantor Stock in Your Portfolio for Now (Zacks)
07:57AM	Here's Why You Should Retain Cencora Stock in Your Portfolio Now (Zacks)
12:11PM	Loading…
Jan-07-26 12:11PM	ANGO Stock Dips Despite Q2 Earnings Beat, Gross Margin Improves (Zacks)
12:07PM	Here's Why You Should Add PacBio Stock to Your Portfolio (Zacks)
Jan-06-26 12:34PM	CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection (Zacks)
07:05AM	OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth (Zacks)
Jan-05-26 04:05PM	Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 9, 2026 (Business Wire)
Jan-02-26 11:36AM	INBS Stock Surges 132.4% on New Manufacturing Partnership (Zacks)
08:33AM	Here's Why You Should Add Inogen Stock to Your Portfolio Now (Zacks)
Dec-31-25 06:15PM	Why Medpace (MEDP) Dipped More Than Broader Market Today (Zacks)
10:52AM	Reasons to Hold HealthEquity Stock in Your Portfolio for Now (Zacks)
10:49AM	CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform (Zacks)
Dec-30-25 12:45PM	ESTA Shares Dip Despite FDA Filing for Motiva Breast Reconstruction (Zacks)
Dec-29-25 11:42AM	Reasons to Hold Veeva Systems Stock in Your Portfolio for Now (Zacks)
Dec-26-25 11:40AM	BTSG or MEDP: Which Is the Better Value Stock Right Now? (Zacks)
Dec-24-25 12:29PM	Reasons to Hold AngioDynamics Stock in Your Portfolio for Now (Zacks)
Dec-23-25 12:07PM	BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens (Zacks)
06:30AM	Strategists are bullish on healthcare in 2026: 3 top stock picks (Yahoo Finance Video)
Dec-22-25 07:51AM	Here's Why You Should Retain INSP Stock in Your Portfolio Now (Zacks)
Dec-19-25 06:15PM	Medpace (MEDP) Outperforms Broader Market: What You Need to Know (Zacks)
10:25AM	PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial (Zacks)
08:41AM	Revvity Advances AI-Driven Scientific Discovery With Signals Xynthetica (Zacks)
Dec-18-25 11:00AM	ECL Boosts High-Tech Water Platform With Ovivo's Electronics Business (Zacks)
09:07AM	Here's Why You Should Hold DaVita Stock in Your Portfolio for Now (Zacks)
08:28AM	Here's Why You Should Retain CLOV Stock in Your Portfolio Now (Zacks)
Dec-17-25 12:02PM	GEHC Expands Healthcare Access Through Indonesia MoH Partnership Deal (Zacks)
11:58AM	Here's Why You Should Hold DexCom Stock in Your Portfolio for Now (Zacks)
Dec-15-25 10:24AM	BAX Highlights EMR-Integrated Smart Pumps Boost Patient Safety & Care (Zacks)
09:13AM	Medpace Holdings (MEDP) Surged Following the Strong Results (Insider Monkey)
Dec-12-25 10:30AM	ATRC Treats First Patients Using Novel Dual-Energy PFA-RFA Platform (Zacks)
09:38AM	Hims & Hers Expands Weight-Management Program to the United Kingdom (Zacks)
Dec-11-25 12:51PM	MOH, Aeroflow Team Up to Offer Virtual Diabetes Care in South Carolina (Zacks)
08:32AM	Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now (Zacks)
07:17AM	BEAT Secures FDA Nod for First Cable-Free At-Home 12-Lead ECG System (Zacks)
07:12AM	Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now (Zacks)
Dec-10-25 11:40AM	BTSG vs. MEDP: Which Stock Is the Better Value Option? (Zacks)
08:59AM	Here's Why You Should Add Cencora Stock to Your Portfolio Now (Zacks)
08:05AM	Reasons to Retain TransMedics Stock in Your Portfolio for Now (Zacks)
Dec-09-25 09:00AM	What Makes Medpace Holdings (MEDP) an Investment Choice? (Insider Monkey)
07:28AM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now (Zacks)
07:28AM	CARL Launches Aprevo Cervical Platform for Personalized Spine Surgery (Zacks)
Dec-08-25 10:27AM	CONMED Stock Falls as It Strategically Exits Gastroenterology Portfolio (Zacks)
Dec-05-25 11:47AM	GEHC Forms 7-Year Care Alliance to Advance URMC Imaging & Monitoring (Zacks)
09:11AM	COO Gains as Q4 Earnings & Sales Beat Estimates, MyDay Adoption Rises (Zacks)
09:04AM	Here's Why You Should Add Inogen Stock to Your Portfolio Now (Zacks)
Dec-04-25 12:17PM	Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics (Investor's Business Daily) -5.50%
11:33AM	HealthEquity Stock Gains as Q3 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
11:30AM	GEHC and Mayo Clinic Launch GEMINI-RT to Aid Personalized Cancer Care (Zacks)
08:55AM	Medpace Holdings, Inc. (MEDP): A Bull Case Theory (Insider Monkey)
Dec-02-25 12:56PM	Here's Why You Should Retain Ecolab Stock in Your Portfolio Now (Zacks)
12:49PM	GEHC Unveils Allia Moveo to Elevate Mobility in Interventional Care (Zacks)
Dec-01-25 11:47AM	GE HealthCare Unveils Next-Gen SIGNA MRI Systems to Elevate Efficiency (Zacks)
Nov-28-25 12:44PM	Here's Why You Should Retain Glaukos Stock in Your Portfolio (Zacks)
Nov-24-25 10:31PM	Medpace (NASDAQ:MEDP): Strongest Q3 Results from the Drug Development Inputs & Services Group (StockStory)
05:15PM	Stock Market Roars To Key Level As Tesla, Palantir, Broadcom Jump; What To Do Now (Investor's Business Daily)
11:40AM	BTSG or MEDP: Which Is the Better Value Stock Right Now? (Zacks)
11:09AM	GE HealthCare to Acquire Intelerad for $2.3B to Boost Cloud Imaging (Zacks)
07:53AM	Should You Hold Quest Diagnostics Stock in Your Portfolio for Now? (Zacks)
Nov-22-25 08:00AM	S&P 500 Retailer Leads Five Resilient Stocks After Nvidia-Led Market Sell-Off (Investor's Business Daily)
Nov-21-25 10:53AM	Veeva Systems Stock Down Despite Q3 Earnings & Revenues Top Estimates (Zacks)
10:50AM	Reasons to Hold AngioDynamics Stock in Your Portfolio for Now (Zacks)
08:20AM	Medpace (MEDP) Surged Following Better-Than-Expected Results (Insider Monkey)
08:11AM	LH Shares Gain Following Publication of New Plasma Detect MRD Data (Zacks)
Nov-20-25 09:34AM	Reasons to Add HealthEquity Stock to Your Portfolio for Now (Zacks)
09:16AM	DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal (Zacks)
07:50AM	EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth? (Zacks)
07:49AM	TMO Stock May Rise Post New PCR Test in Collab With Coca-Cola Partner (Zacks)
Nov-18-25 04:05PM	Why IBD Stock Of The Day Medpace, Up 78% In 2025, Is Easily Outpacing Its Peers (Investor's Business Daily)
12:45PM	Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
11:39AM	BFLY Stock Down Despite Launching Compass AI to Drive POCUS Programs (Zacks)
09:31AM	Medtronic's Q2 Earnings & Revenues Beat Estimates, Stock Climbs (Zacks)
Nov-17-25 12:39PM	Ecolab Launches Integrated Cooling Platform to Support AI Data Centers (Zacks)

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The firm's services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. It operates through the following geographical segments: United States, Europe, Belgium, Asia-Pacific, and Other. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carley Brian T	Director	Feb 13 '26	Option Exercise	54.99	6,472	355,895	32,753	Feb 17 04:59 PM
BURWIG SUSAN E	Exec. VP, Operations	Feb 13 '26	Option Exercise	107.93	10,984	1,185,503	58,484	Feb 17 04:43 PM
BURWIG SUSAN E	Exec. VP, Operations	Dec 05 '25	Option Exercise	107.93	10,000	1,079,300	47,500	Dec 09 04:14 PM
Troendle August J.	CEO	Dec 03 '25	Sale	590.69	668	394,581	646,184	Dec 04 04:26 PM
BURWIG SUSAN E	Exec. VP, Operations	Dec 02 '25	Option Exercise	107.93	10,000	1,079,300	37,500	Dec 04 04:21 PM
Troendle August J.	CEO	Dec 01 '25	Sale	593.25	23,178	13,750,348	652,550	Dec 03 04:28 PM
Troendle August J.	CEO	Dec 02 '25	Sale	590.47	5,698	3,364,498	646,852	Dec 03 04:28 PM
Troendle August J.	CEO	Nov 26 '25	Sale	606.88	41,331	25,082,957	690,879	Dec 01 04:48 PM
Troendle August J.	CEO	Nov 28 '25	Sale	593.46	15,151	8,991,512	675,728	Dec 01 04:48 PM
Troendle August J.	CEO	Nov 24 '25	Sale	607.78	59,025	35,874,214	774,602	Nov 26 04:29 PM
Troendle August J.	CEO	Nov 25 '25	Sale	615.52	42,392	26,093,124	732,210	Nov 26 04:29 PM
BURWIG SUSAN E	Exec. VP, Operations	Nov 24 '25	Sale	609.15	20,000	12,183,000	27,500	Nov 26 04:22 PM
August J. Troendle	Chairman	Nov 25 '25	Proposed Sale	615.00	150,000	92,250,000		Nov 25 04:43 PM
Brady Kevin M.	CFO & Treasurer	Nov 21 '25	Option Exercise	166.73	3,000	500,190	9,000	Nov 25 04:40 PM
Brady Kevin M.	CFO & Treasurer	Nov 21 '25	Sale	590.35	3,000	1,771,050	6,000	Nov 25 04:40 PM
Troendle August J.	CEO	Nov 21 '25	Sale	592.18	21,858	12,943,870	833,627	Nov 24 04:20 PM
Troendle August J.	CEO	Nov 20 '25	Sale	598.49	6,830	4,087,687	855,485	Nov 24 04:20 PM
BURWIG SUSAN E	Officer	Nov 24 '25	Proposed Sale	609.15	20,000	12,183,035		Nov 24 02:03 PM
Brady Kevin M.	Officer	Nov 21 '25	Proposed Sale	590.35	3,000	1,771,051		Nov 21 01:43 PM
Troendle August J.	CEO	Nov 19 '25	Sale	592.07	23,862	14,127,974	862,315	Nov 20 04:14 PM
Troendle August J.	CEO	Nov 18 '25	Sale	590.84	7,191	4,248,730	886,177	Nov 20 04:14 PM
Kraft Robert O.	Director	Nov 14 '25	Option Exercise	54.99	6,472	355,895	7,305	Nov 18 05:02 PM
Kraft Robert O.	Director	Nov 14 '25	Sale	591.85	6,472	3,830,453	833	Nov 18 05:02 PM
Troendle August J.	CEO	Nov 14 '25	Sale	595.26	14,747	8,778,299	899,415	Nov 18 04:51 PM
Troendle August J.	CEO	Nov 17 '25	Sale	591.00	6,047	3,573,777	893,368	Nov 18 04:51 PM
Troendle August J.	CEO	Nov 12 '25	Sale	603.23	5,312	3,204,358	919,290	Nov 14 04:41 PM
Troendle August J.	CEO	Nov 13 '25	Sale	601.37	5,128	3,083,825	914,162	Nov 14 04:41 PM
Kraft Robert O.	Director	Nov 14 '25	Proposed Sale	591.85	6,472	3,830,434		Nov 14 04:12 PM
August J. Troendle	Chairman	Nov 12 '25	Proposed Sale	600.00	150,000	90,000,000		Nov 12 04:53 PM
BURWIG SUSAN E	Exec. VP, Operations	Nov 11 '25	Sale	605.00	18,000	10,890,000	47,500	Nov 12 10:10 AM
BURWIG SUSAN E	Officer	Nov 11 '25	Proposed Sale	605.00	18,000	10,890,000		Nov 12 07:52 AM
GEIGER JESSE J	President	Nov 05 '25	Sale	595.66	21,503	12,808,477	15,000	Nov 07 04:38 PM
GEIGER JESSE J	Officer	Nov 05 '25	Proposed Sale	595.66	21,503	12,808,442		Nov 05 04:20 PM
DAVENPORT FRED B JR	Director	Oct 30 '25	Option Exercise	54.99	6,472	355,895	9,470	Nov 03 04:46 PM
DAVENPORT FRED B JR	Director	Oct 30 '25	Sale	581.88	5,972	3,474,987	3,498	Nov 03 04:46 PM
DAVENPORT FRED B JR	Director	Oct 30 '25	Proposed Sale	581.88	5,972	3,474,993		Oct 30 10:38 AM
GEIGER JESSE J	President	Oct 27 '25	Option Exercise	166.73	19,460	3,244,566	55,963	Oct 29 05:12 PM
GEIGER JESSE J	President	Oct 29 '25	Option Exercise	166.73	3,568	594,893	40,071	Oct 29 05:12 PM
GEIGER JESSE J	President	Oct 27 '25	Sale	605.12	19,460	11,775,635	36,503	Oct 29 05:12 PM
GEIGER JESSE J	President	Oct 29 '25	Sale	585.00	3,568	2,087,280	36,503	Oct 29 05:12 PM
EWALD STEPHEN P	General Counsel & Corp. Secy.	Oct 27 '25	Option Exercise	166.73	18,230	3,039,488	28,573	Oct 29 04:58 PM
EWALD STEPHEN P	General Counsel & Corp. Secy.	Oct 27 '25	Sale	598.85	15,230	9,120,486	13,343	Oct 29 04:58 PM
BURWIG SUSAN E	Exec. VP, Operations	Oct 27 '25	Sale	605.01	2,000	1,210,020	65,500	Oct 29 04:52 PM
GEIGER JESSE J	Officer	Oct 29 '25	Proposed Sale	585.00	3,568	2,087,280		Oct 29 10:29 AM
GEIGER JESSE J	Officer	Oct 27 '25	Proposed Sale	605.12	19,460	11,775,659		Oct 27 04:08 PM
BURWIG SUSAN E	Officer	Oct 27 '25	Proposed Sale	605.01	2,000	1,210,016		Oct 27 04:07 PM
EWALD STEPHEN P	Officer	Oct 27 '25	Proposed Sale	598.85	15,230	9,120,538		Oct 27 10:30 AM
BURWIG SUSAN E	Exec. VP, Operations	Sep 26 '25	Option Exercise	107.93	10,000	1,079,300	67,500	Sep 30 04:15 PM
BURWIG SUSAN E	Exec. VP, Operations	Sep 03 '25	Sale	480.00	10,000	4,800,000	57,500	Sep 05 04:16 PM
BURWIG SUSAN E	Officer	Sep 03 '25	Proposed Sale	480.00	10,000	4,800,019		Sep 03 04:49 PM
Troendle August J.	CEO	Aug 29 '25	Sale	475.90	36,196	17,225,676	925,799	Sep 03 04:10 PM
Troendle August J.	CEO	Sep 02 '25	Sale	475.11	1,197	568,707	924,602	Sep 03 04:10 PM
Troendle August J.	CEO	Aug 27 '25	Sale	475.00	620	294,500	961,995	Aug 28 04:23 PM
BURWIG SUSAN E	Exec. VP, Operations	Aug 26 '25	Option Exercise	107.93	10,000	1,079,300	67,500	Aug 28 04:10 PM
August J. Troendle	Chairman	Aug 27 '25	Proposed Sale	475.00	38,013	18,056,018		Aug 27 05:09 PM
McCarthy Cornelius P. III	Director	Aug 19 '25	Sale	465.04	1,662	772,896	10,197	Aug 21 04:56 PM
McCarthy Cornelius P. III	Director	Aug 19 '25	Proposed Sale	465.04	1,662	772,894		Aug 19 03:00 PM
EWALD STEPHEN P	General Counsel & Corp. Secy.	Jul 28 '25	Sale	450.00	3,000	1,350,000	10,343	Jul 29 06:02 PM
BURWIG SUSAN E	Exec. VP, Operations	Jul 28 '25	Sale	450.14	7,500	3,376,050	57,500	Jul 29 05:43 PM
Troendle August J.	CEO	Jul 28 '25	Sale	451.69	48,487	21,901,093	962,615	Jul 29 05:37 PM
GEIGER JESSE J	President	Jul 24 '25	Option Exercise	107.93	41,801	4,511,582	78,304	Jul 28 05:37 PM
GEIGER JESSE J	President	Jul 24 '25	Sale	453.11	41,801	18,940,451	36,503	Jul 28 05:37 PM
Brady Kevin M.	CFO & Treasurer	Jul 24 '25	Option Exercise	57.94	12,000	695,280	18,000	Jul 28 05:08 PM
Brady Kevin M.	CFO & Treasurer	Jul 24 '25	Sale	454.23	12,000	5,450,760	6,000	Jul 28 05:08 PM
BURWIG SUSAN E	Officer	Jul 28 '25	Proposed Sale	450.14	7,500	3,376,083		Jul 28 04:50 PM
August J. Troendle	Chairman	Jul 28 '25	Proposed Sale	451.68	356,446	161,001,311		Jul 28 04:35 PM
EWALD STEPHEN P	Officer	Jul 28 '25	Proposed Sale	450.00	3,000	1,350,000		Jul 28 03:27 PM
McCarthy Cornelius P. III	Director	Jul 22 '25	Option Exercise	54.99	1,972	108,440	11,859	Jul 24 04:31 PM
Brady Kevin M.	Officer	Jul 24 '25	Proposed Sale	454.23	12,000	5,450,751		Jul 24 04:13 PM
GEIGER JESSE J	Officer	Jul 24 '25	Proposed Sale	453.11	41,801	18,940,252		Jul 24 04:09 PM
McCarthy Cornelius P. III	Director	Jul 18 '25	Option Exercise	54.99	4,500	247,455	9,887	Jul 22 04:36 PM
DAVENPORT FRED B JR	Director	Apr 24 '25	Option Exercise	57.17	4,710	269,271	4,710	Apr 28 04:39 PM
DAVENPORT FRED B JR	Director	Apr 24 '25	Sale	301.82	1,712	516,716	2,998	Apr 28 04:39 PM
DAVENPORT FRED B JR	Director	Apr 24 '25	Proposed Sale	301.82	1,712	516,716		Apr 24 02:13 PM
Troendle August J.	CEO	Mar 07 '25	Option Exercise	68.62	356,446	24,458,835	1,011,102	Mar 10 05:47 PM
EWALD STEPHEN P	General Counsel & Corp. Secy.	Feb 27 '25	Buy	326.11	2	652	13,343	Feb 28 04:39 PM
Carley Brian T	Director	Feb 24 '25	Option Exercise	42.62	8,127	346,373	30,035	Feb 26 04:18 PM
Carley Brian T	Director	Feb 24 '25	Sale	345.59	4,003	1,383,397	26,032	Feb 26 04:18 PM
Carley Brian T	Director	Feb 24 '25	Proposed Sale	345.59	4,003	1,383,385		Feb 24 12:52 PM

Open in Screener

MXCT

MaxCyte Inc

Feb 17 • 04:00PM ET

0.7001

-0.0195 -2.71 %

Healthcare • Medical Devices • USA • NASD

Peers: NTLA CRSP EDIT SGMO BEAM CRBU CDXS ABCL ALLO

| Held by: VTI IWM VXF IWN VTWO VHT IWC DFAS ITOT VTWV

Index	RUT	P/E	-	EPS (ttm)	-0.43	Insider Own	7.52%	Shs Outstand	106.64M	Perf Week	-11.54%
Market Cap	74.68M	Forward P/E	-	EPS next Y	-0.27	Insider Trans	-0.13%	Shs Float	98.66M	Perf Month	-45.73%
Enterprise Value	-12.89M	PEG	-	EPS next Q	-0.08	Inst Own	73.54%	Short Float	3.93%	Perf Quarter	-53.64%
Income	-45.63M	P/S	2.17	EPS this Y	6.07%	Inst Trans	9.71%	Short Ratio	3.23	Perf Half Y	-48.52%
Sales	34.42M	P/B	0.41	EPS next Y	25.28%	ROA	-19.75%	Short Interest	3.88M	Perf YTD	-54.83%
Book/sh	1.69	P/C	0.71	EPS next 5Y	14.43%	ROE	-23.19%	52W High	4.32 -83.79%	Perf Year	-83.21%
Cash/sh	0.99	P/FCF	-	EPS past 3/5Y	-22.97% -11.37%	ROIC	-23.15%	52W Low	0.68 2.87%	Perf 3Y	-85.56%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.45% 12.31%	Gross Margin	67.76%	Volatility	9.69% 9.49%	Perf 5Y	-92.53%
Dividend TTM	-	EV/Sales	-0.37	EPS Y/Y TTM	-25.71%	Oper. Margin	-144.34%	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.27	Sales Y/Y TTM	-24.52%	Profit Margin	-132.58%	RSI (14)	16.34	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	7.74	EPS Q/Q	-5.91%	SMA20	-24.57%	Beta	1.24	Target Price	6.07
Payout	-	Debt/Eq	0.10	Sales Q/Q	-16.35%	SMA50	-44.81%	Rel Volume	1.15	Prev Close	0.72
Employees	114	LT Debt/Eq	0.09	Earnings	Nov 12 AMC	SMA200	-59.05%	Avg Volume	1.20M	Price	0.70
IPO	Dec 05, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-7.24% 0.00%	Trades		Volume	1,397,498	Change	-2.71%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-11-25	Downgrade	BTIG Research	Buy → Neutral
Aug-07-25	Downgrade	William Blair	Outperform → Mkt Perform
Jul-22-25	Initiated	Stephens	Overweight	$6
Nov-29-23	Initiated	Craig Hallum	Buy	$7
Oct-15-21	Resumed	Cowen	Outperform
Aug-24-21	Initiated	William Blair	Outperform
Aug-24-21	Initiated	Wedbush	Outperform	$36
Aug-24-21	Initiated	Stifel	Buy	$18
Aug-24-21	Initiated	Stephens	Overweight	$19
Aug-24-21	Initiated	Cowen	Outperform
Aug-24-21	Initiated	BTIG Research	Buy	$22

Show Previous Ratings

Jan-12-26 08:05AM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Dec-01-25 09:00AM	Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO (Business Wire) -7.39%
Nov-13-25 12:01AM	MaxCyte Inc (MXCT) Q3 2025 Earnings Call Highlights: Strategic Moves Amidst Market Challenges (GuruFocus.com)
Nov-12-25 04:08PM	MaxCyte Announces Planned CFO Transition in 2026 (GlobeNewswire)
04:05PM	MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance (GlobeNewswire)
05:25PM	Loading…
Nov-10-25 05:25PM	Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +5.44%
Nov-07-25 08:05AM	ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates (Zacks)
Nov-05-25 08:05AM	MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance (GlobeNewswire)
Oct-08-25 08:05AM	MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire) +9.68%
Oct-06-25 08:05AM	MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors (GlobeNewswire)
Sep-22-25 04:30PM	MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability (GlobeNewswire) +10.32%
Aug-11-25 07:45AM	MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio (Insider Monkey)
Aug-06-25 06:10PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -29.90%
04:05PM	MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance (GlobeNewswire)
Aug-05-25 10:27AM	MaxCyte Inc (MXCT) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
08:05AM	Loading…
Aug-04-25 08:05AM	MaxCyte Signs Platform License Agreement with Adicet Bio (GlobeNewswire)
Jul-31-25 08:05AM	MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline (GlobeNewswire)
Jul-09-25 08:05AM	MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-01-25 01:00AM	PHC Announces Exclusive Distribution of MaxCyte® ExPERT Platform in Japan (Business Wire)
Jun-11-25 02:00AM	MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies (GlobeNewswire)
May-13-25 10:51AM	MaxCyte, Inc. (MXCT): A Bull Case Theory (Insider Monkey)
May-08-25 03:27AM	MaxCyte Inc (MXCT) Q1 2025 Earnings Call Highlights: Strong Revenue Alignment Amidst Growth ... (GuruFocus.com) -11.31%
May-07-25 06:30PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance (GlobeNewswire)
Apr-10-25 02:00AM	MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire) -7.51%
Apr-08-25 09:35AM	Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT) (Zacks) -5.67%
Apr-07-25 09:35AM	Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround (Zacks)
Apr-04-25 12:00PM	MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know (Zacks) -5.77%
Mar-12-25 03:07AM	MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges (GuruFocus.com) -8.36%
Mar-11-25 04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance (GlobeNewswire)
02:00AM	Loading…
Feb-12-25 02:00AM	MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs (GlobeNewswire)
Feb-07-25 02:00AM	MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference (GlobeNewswire)
Jan-30-25 02:00AM	MaxCyte Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments (GlobeNewswire)
Jan-15-25 12:00PM	All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy (Zacks)
Jan-13-25 03:05AM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) +11.59%
Dec-23-24 02:00AM	MaxCyte Announces Retirement of Board Member Art Mandell (GlobeNewswire)
Dec-09-24 02:00AM	MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance (GlobeNewswire) +15.83%
Nov-13-24 08:05AM	MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics (GlobeNewswire)
Nov-07-24 02:00PM	MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ... (GuruFocus.com) -10.82%
Nov-06-24 05:55PM	MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Oct-31-24 08:05AM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-16-24 12:00PM	MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Oct-15-24 08:05AM	MaxCyte Appoints Cynthia Collins to its Board of Directors (GlobeNewswire)
Oct-11-24 08:05AM	MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-10-24 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer (GlobeNewswire)
Oct-09-24 05:08PM	MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges (GuruFocus.com) -5.41%
Sep-17-24 03:32AM	MaxCyte and Kamau Therapeutics sign platform license agreement (Pharmaceutical Technology)
Sep-16-24 02:00AM	MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases (GlobeNewswire)
Sep-05-24 04:05PM	MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference (GlobeNewswire)
Aug-06-24 05:50PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.31%
04:05PM	MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Jul-17-24 08:50AM	MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jul-09-24 04:05PM	MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jun-13-24 09:55AM	Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect? (Zacks)
08:50AM	Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why (Zacks)
Jun-11-24 01:30AM	Insider Buying: President and CEO Maher Masoud Acquires 100,000 Shares of MaxCyte Inc (MXCT) (GuruFocus.com) -5.65%
May-29-24 08:05AM	MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference (GlobeNewswire)
May-22-24 08:05AM	MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development (GlobeNewswire)
May-12-24 08:19AM	MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 02:39PM	MaxCyte Shares Rise Sharply After Q1 Results Beat (MT Newswires) +18.07%
06:35AM	Q1 2024 MaxCyte Inc Earnings Call (Thomson Reuters StreetEvents)
03:58AM	MaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
May-07-24 08:58PM	MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:45PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance (GlobeNewswire)
Apr-10-24 08:05AM	MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-02-24 08:05AM	MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) (GlobeNewswire)
Mar-14-24 08:15AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 08:17AM	11 Oversold Healthcare Stocks To Buy Right Now (Insider Monkey)
Mar-12-24 05:31PM	MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance (GlobeNewswire)
Mar-04-24 04:05PM	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results (GlobeNewswire) -12.21%
Feb-09-24 08:05AM	MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-24 08:05AM	MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugens Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers (GlobeNewswire)
Jan-23-24 08:05AM	MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs (GlobeNewswire)
Jan-08-24 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +13.73%
Jan-03-24 08:05AM	MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline (GlobeNewswire) -11.60%
Jan-02-24 02:00AM	MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director (GlobeNewswire) +6.38%
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey) +9.01%
Dec-11-23 04:05PM	MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023 (GlobeNewswire)
Dec-07-23 11:05AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Dec-02-23 09:04AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Nov-16-23 08:05AM	MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member (GlobeNewswire)
Nov-09-23 12:57PM	MaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:05PM	MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance (GlobeNewswire)
Nov-06-23 04:05PM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-05-23 12:59PM	Why Shares of MaxCyte Are Plummeting on Thursday (Motley Fool) -20.64%
08:47AM	Why Is MaxCyte (MXCT) Stock Down 21% Today? (InvestorPlace)
Oct-04-23 04:05PM	MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance (GlobeNewswire) +9.00%
Sep-06-23 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing (GlobeNewswire)
Sep-05-23 08:05AM	MaxCyte to Participate in Baird Global Healthcare Conference (GlobeNewswire)
Aug-09-23 04:05PM	MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire) -10.44%
Aug-01-23 08:05AM	MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients (GlobeNewswire)
Jul-13-23 08:05AM	MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023 (GlobeNewswire)
Jul-10-23 08:05AM	MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies (GlobeNewswire) +7.78%
Jul-08-23 04:54AM	MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 77% of the company (Simply Wall St.)
Jul-06-23 08:05AM	MaxCyte Signs Strategic Platform License with Lyell Immunopharma (GlobeNewswire)
Jun-01-23 04:05PM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.56%
May-30-23 08:18AM	Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth (Simply Wall St.)

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hemrajani Rekha	Director	Jun 25 '25	Sale	2.09	10,684	22,378	39,893	Aug 27 05:12 PM
Swirsky Douglas J	CHIEF FINANCIAL OFFICER	Aug 13 '25	Buy	1.29	50,000	64,500	161,811	Aug 13 07:48 PM
Masoud Maher	President and CEO	Aug 13 '25	Buy	1.37	75,000	102,915	175,000	Aug 13 07:47 PM
Erck Stanley C	Director	Aug 13 '25	Buy	1.37	100,000	137,220	398,328	Aug 13 07:47 PM
DOUGLAS RICHARD	Director	Aug 13 '25	Buy	1.39	80,000	111,040	230,577	Aug 13 07:46 PM
Brooke William W	Director	Aug 13 '25	Buy	1.29	50,000	64,500	150,879	Aug 13 07:45 PM
Hemrajani Rekha	Director	Jun 25 '25	Proposed Sale	2.09	10,684	22,378		Jun 25 04:05 PM
Soleymannezhad Ali	Chief Commercial Officer	Mar 18 '25	Sale	3.18	1,211	3,850	59,439	Mar 20 06:49 PM
Sandoval David I.	GENERAL COUNSEL	Mar 18 '25	Sale	3.18	353	1,122	64,219	Mar 20 06:47 PM
Swirsky Douglas J	CHIEF FINANCIAL OFFICER	Mar 18 '25	Sale	3.18	6,939	22,061	111,811	Mar 20 06:08 PM

Open in Screener

IQV

IQVIA Holdings Inc

Feb 17 • 04:00PM ET

164.44

-2.50 -1.50 %

Healthcare • Diagnostics & Research • USA • NYSE

IQV IQVIA Holdings Inc daily Stock Chart

Peers: CROX MEDP LH ICON CTLT CRL INCY

| Held by: VTI VOO VO IVV VTV SPY VOE XLV RSP VHT

Index	S&P 500	P/E	20.93	EPS (ttm)	7.86	Insider Own	0.96%	Shs Outstand	169.60M	Perf Week	-14.65%
Market Cap	28.00B	Forward P/E	11.69	EPS next Y	14.07	Insider Trans	-5.61%	Shs Float	168.67M	Perf Month	-31.85%
Enterprise Value	42.25B	PEG	1.24	EPS next Q	2.83	Inst Own	101.47%	Short Float	2.71%	Perf Quarter	-26.44%
Income	1.36B	P/S	1.72	EPS this Y	6.57%	Inst Trans	-1.47%	Short Ratio	2.67	Perf Half Y	-13.95%
Sales	16.30B	P/B	4.29	EPS next Y	10.74%	ROA	4.79%	Short Interest	4.56M	Perf YTD	-27.05%
Book/sh	38.34	P/C	13.08	EPS next 5Y	9.45%	ROE	21.64%	52W High	247.04 -33.44%	Perf Year	-14.99%
Cash/sh	12.57	P/FCF	13.65	EPS past 3/5Y	11.05% 40.52%	ROIC	6.53%	52W Low	134.65 22.13%	Perf 3Y	-25.16%
Dividend Est.	-	EV/EBITDA	12.34	Sales past 3/5Y	4.18% 7.50%	Gross Margin	26.25%	Volatility	5.72% 4.84%	Perf 5Y	-12.96%
Dividend TTM	-	EV/Sales	2.59	EPS Y/Y TTM	4.62%	Oper. Margin	13.99%	ATR (14)	9.60	Perf 10Y	160.31%
Dividend Ex-Date	-	Quick Ratio	0.75	Sales Y/Y TTM	5.84%	Profit Margin	8.34%	RSI (14)	20.93	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	0.75	EPS Q/Q	23.71%	SMA20	-21.58%	Beta	1.42	Target Price	238.58
Payout	0.00%	Debt/Eq	2.50	Sales Q/Q	10.13%	SMA50	-25.82%	Rel Volume	1.25	Prev Close	166.94
Employees	93000	LT Debt/Eq	2.20	Earnings	Feb 05 BMO	SMA200	-14.64%	Avg Volume	1.71M	Price	164.44
IPO	May 09, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.64% 2.93%	Trades		Volume	2,212,481	Change	-1.50%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Resumed	Morgan Stanley	Overweight	$265
Nov-13-25	Initiated	BMO Capital Markets	Outperform	$260
Nov-03-25	Downgrade	TD Cowen	Buy → Hold	$215
Oct-29-25	Upgrade	Robert W. Baird	Neutral → Outperform	$258
Oct-09-25	Upgrade	HSBC Securities	Hold → Buy	$235
Sep-09-25	Upgrade	Jefferies	Hold → Buy	$225
Apr-25-25	Downgrade	HSBC Securities	Buy → Hold	$160
Apr-10-25	Downgrade	Barclays	Overweight → Equal Weight	$170
Feb-03-25	Downgrade	BTIG Research	Buy → Neutral
Dec-20-24	Initiated	Stephens	Overweight	$250
Oct-14-24	Initiated	Redburn Atlantic	Buy
Sep-04-24	Initiated	RBC Capital Mkts	Outperform	$275
Jul-24-24	Downgrade	Jefferies	Buy → Hold	$266 → $242
Jun-06-24	Initiated	Goldman	Buy	$270
Feb-26-24	Initiated	Leerink Partners	Outperform	$290
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Feb-13-24	Initiated	BTIG Research	Buy	$285
Nov-02-23	Downgrade	Robert W. Baird	Outperform → Neutral	$248 → $202
Sep-06-23	Initiated	HSBC Securities	Buy	$260
Mar-17-23	Initiated	Truist	Buy	$265

Show Previous Ratings

Feb-17-26 11:46AM	Waste Connections Stock Slides 7% Since Q4 Earnings Beat Estimates (Zacks)
Feb-13-26 08:32AM	Is the Options Market Predicting a Spike in IQVIA Stock? (Zacks)
Feb-12-26 12:30PM	Insperity Stock Price Decreases 18% After Reporting Loss in Q4 (Zacks)
12:36AM	The Top 5 Analyst Questions From IQVIA's Q4 Earnings Call (StockStory)
Feb-11-26 07:19PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
08:00AM	Loading…
Feb-10-26 08:00AM	IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions (Business Wire) -5.30%
Feb-08-26 08:39AM	Gartner, Stellantis, And Novo Nordisk Are Among Top 10 Large Cap Losers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio? (Benzinga)
Feb-06-26 07:21PM	IQVIA Q4 Earnings Call Highlights (MarketBeat)
09:40AM	Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term (Zacks)
12:54AM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
12:35AM	IQV Q4 Deep Dive: Market Cautions Despite Revenue Beat and AI Strategy Emphasis (StockStory)
Feb-05-26 04:00PM	IQVIA Holdings Inc (IQV) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -10.65%
12:11PM	IQVIA Q4 Earnings & Revenues Beat Estimates, Increase Y/Y (Zacks)
11:55AM	IQVIA (IQV) Stock Trades Down, Here Is Why (StockStory)
09:07AM	IQVIA backs AI strategy as analysts question impact on business (Reuters)
08:15AM	Loading…
08:15AM	IQVIA Holdings (IQV) Q4 Earnings and Revenues Top Estimates (Zacks)
07:36AM	IQVIA's (NYSE:IQV) Q4 CY2025 Sales Top Estimates (StockStory)
07:20AM	IQVIA: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance (Business Wire)
Feb-04-26 11:40AM	IQV or IDXX: Which Is the Better Value Stock Right Now? (Zacks)
Feb-03-26 10:14PM	IQVIA (IQV) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory) -11.88%
11:23AM	IQVIA Set to Report Q4 Earnings: Here's What You Should Know (Zacks)
09:15AM	Unlocking Q4 Potential of IQVIA (IQV): Exploring Wall Street Estimates for Key Metrics (Zacks)
Jan-29-26 08:00AM	IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration (Business Wire)
Jan-25-26 11:44AM	Beyond Biotech-3 Healthcare Stocks for Growth-Minded Investors (MarketBeat)
Jan-22-26 04:05PM	IQVIA Named to the Fortune Worlds Most Admired Companies List, Ranked No. 1 in Its Sector for Fifth Consecutive Year (Business Wire)
Jan-20-26 04:45PM	IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026 (Business Wire)
Jan-15-26 09:36AM	3 Medical Device Companies in Focus for Monetizing Data and Analytics (Zacks)
Jan-14-26 09:50AM	Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-13-26 09:11AM	What You Need To Know Ahead of IQVIAs Earnings Release (Barchart)
11:36PM	Loading…
Jan-12-26 11:36PM	2 Large-Cap Stocks Worth Your Attention and 1 We Turn Down (StockStory)
Jan-11-26 11:04PM	3 Reasons to Sell IQV and 1 Stock to Buy Instead (StockStory)
Jan-09-26 09:40AM	Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term (Zacks)
Dec-29-25 12:55PM	Here's Why You Should Retain IQV Stock in Your Portfolio Now (Zacks)
Dec-17-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-09-25 10:19AM	Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run? (Zacks)
09:50AM	Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term (Zacks)
Dec-04-25 12:21PM	Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics (Investor's Business Daily)
Dec-03-25 10:32PM	Is IQVIA Holdings Stock Outperforming the S&P 500? (Barchart)
Dec-02-25 08:00AM	IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform (Business Wire)
Nov-28-25 11:30AM	Glaukos (GKOS) Up 20% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-27-25 11:30AM	Why Is IQVIA (IQV) Up 6.4% Since Last Earnings Report? (Zacks)
Nov-26-25 09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
Nov-11-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-06-25 10:32PM	Q3 Earnings Highs And Lows: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory)
12:38PM	GDOT Gears Up to Report Q3 Earnings: Here's What You Should Know (Zacks)
12:33PM	Mogo Set to Report Q3 Earnings: Here's What Investors Should Know (Zacks)
Nov-05-25 04:15PM	Dr. William G. Kaelin Jr. joins IQVIA Board of Directors (Business Wire)
09:40AM	IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Nov-04-25 12:31AM	IQVIA's Q3 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Nov-03-25 01:15PM	Why IQVIA (IQV) Shares Are Trading Lower Today (StockStory)
09:42AM	Boeing upgraded, Charter downgraded: Wall Street's top analyst calls (The Fly)
Oct-30-25 03:14PM	IQVIA Holdings Inc (IQV) Q3 2025 Earnings Call Highlights: Record Free Cash Flow and Strong ... (GuruFocus.com)
Oct-29-25 03:45PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
01:31AM	IQV Q3 Deep Dive: Clinical Research Demand and AI Initiatives Drive Steady Growth (StockStory)
Oct-28-25 08:00PM	IQVIA (IQV) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
01:09PM	IQVIA Earnings & Revenues Beat Estimates in Q3, Increase Y/Y (Zacks)
08:15AM	IQVIA Holdings (IQV) Tops Q3 Earnings and Revenue Estimates (Zacks)
07:28AM	IQVIA (NYSE:IQV) Beats Q3 Sales Expectations (StockStory)
07:14AM	IQVIA: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	IQVIA Reports Third-Quarter 2025 Results (Business Wire)
Oct-26-25 11:08PM	IQVIA (IQV) Reports Earnings Tomorrow: What To Expect (StockStory)
Oct-23-25 10:19AM	IQVIA Gears Up to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-22-25 10:00AM	TransMedics (TMDX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-21-25 04:15PM	IQVIA CEO Ari Bousbib to Speak at UBS Global Healthcare Conference on November 11, 2025 (Business Wire)
10:00AM	IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-20-25 01:35PM	Why IQVIA (IQV) Stock Is Trading Up Today (StockStory)
Oct-15-25 04:25AM	What to Expect From IQVIA Holdings Next Quarterly Earnings Report (Barchart)
Oct-10-25 12:00AM	3 Reasons to Sell IQV and 1 Stock to Buy Instead (StockStory)
Oct-09-25 09:37AM	Oracle initiated, Roblox upgraded: Wall Street's top analyst calls (The Fly)
Oct-01-25 06:48PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research) +7.29%
04:01PM	Why IQVIA (IQV) Stock Is Trading Up Today (StockStory)
10:10AM	Is Veeva's Vault CRM Emerging as the Standard for Top Biopharma? (Zacks)
Sep-30-25 04:15PM	IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025 (Business Wire) +5.10%
Sep-29-25 09:43AM	What Makes IQVIA (IQV) an Attractive Investment? (Insider Monkey)
Sep-19-25 09:40AM	Here's Why IQVIA Holdings (IQV) is a Strong Value Stock (Zacks)
08:58AM	What Makes IQVIA (IQV) a Good Investment? (Insider Monkey)
Sep-16-25 08:00AM	IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships (Business Wire)
Sep-11-25 02:16PM	Why IQVIA (IQV) Stock Is Up Today (StockStory)
06:09AM	How Is IQVIA Holdings' Stock Performance Compared to Other Health Tech Stocks? (Barchart)
Sep-10-25 08:00AM	IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management (Business Wire)
04:54AM	IQVIA Holdings Inc. (IQV) and Flagship Pioneering Partner to Accelerate Growth of Breakthrough Life Sciences Companies (Insider Monkey)
Sep-09-25 12:11PM	Jefferies backs IQVIA and Charles River, cuts ICON on customer losses (Investing.com)
Sep-03-25 09:40AM	Here's Why IQVIA Holdings (IQV) is a Strong Value Stock (Zacks)
Sep-02-25 09:00AM	IQVIA Announces CFO Transition in Early 2026 (Business Wire)
Aug-29-25 11:30AM	Why Is DexCom (DXCM) Down 7% Since Last Earnings Report? (Zacks)
Aug-28-25 08:00AM	IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies (PR Newswire)
Aug-27-25 09:55AM	IQVIA Holdings Inc. (IQV): A Bull Case Theory (Insider Monkey)
Aug-22-25 08:29AM	What Are Wall Street Analysts' Target Price for IQVIA Holdings Stock? (Barchart)
Aug-21-25 11:30AM	IQVIA (IQV) Down 1.1% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-18-25 11:31PM	Q2 Earnings Highs And Lows: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory)
09:00AM	IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes (Business Wire)
Aug-14-25 09:40AM	Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term (Zacks)
02:42AM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
Aug-13-25 10:57AM	UMAC Gears Up to Report Q2 Earnings: What's in the Offing? (Zacks)
Aug-11-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
05:19AM	Kexing Biopharm Enters Strategic Partnership with IQVIA to Accelerate Global Expansion (PR Newswire)
Aug-06-25 06:42PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
12:24PM	Avis Budget Stock Declines 22% Since Reporting Q2 Earnings Miss (Zacks)
Aug-05-25 12:23PM	Gartner Earnings Surpass Estimates in Q2, Revenues Increase Y/Y (Zacks)

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BOUSBIB ARI	See Remarks	Dec 18 '25	Option Exercise	59.90	50,000	2,995,000	857,163	Dec 19 05:00 PM
BOUSBIB ARI	See Remarks	Dec 18 '25	Sale	222.43	36,564	8,132,931	820,599	Dec 19 05:00 PM
ARI BOUSBIB	Officer	Dec 18 '25	Proposed Sale	222.43	36,564	8,132,876		Dec 18 05:41 PM
Sherbet Eric	See Remarks	Oct 29 '25	Option Exercise	131.82	10,000	1,318,200	31,108	Oct 31 05:01 PM
Sherbet Eric	See Remarks	Oct 29 '25	Sale	219.70	4,000	878,800	27,108	Oct 31 05:01 PM
BOUSBIB ARI	See Remarks	Oct 29 '25	Option Exercise	59.90	77,592	4,647,761	884,755	Oct 31 05:00 PM
BOUSBIB ARI	See Remarks	Oct 29 '25	Sale	220.33	56,557	12,461,119	828,198	Oct 31 05:00 PM
ARI BOUSBIB	Officer	Oct 29 '25	Proposed Sale	220.33	56,557	12,460,983		Oct 29 04:18 PM
ERIC SHERBET	Officer	Oct 29 '25	Proposed Sale	219.70	4,000	878,820		Oct 29 04:10 PM
Cherofsky Keriann	See Remarks	Jul 23 '25	Sale	191.53	549	105,150	2,910	Jul 25 05:01 PM
Sherbet Eric	See Remarks	Jul 23 '25	Option Exercise	97.20	11,870	1,153,764	32,978	Jul 25 05:00 PM
Sherbet Eric	See Remarks	Jul 23 '25	Sale	190.05	5,800	1,102,290	27,178	Jul 25 05:00 PM
ERIC SHERBET	Officer	Jul 23 '25	Proposed Sale	190.05	5,800	1,102,262		Jul 23 05:53 PM
KERIANN CHEROFSKY	Officer	Jul 23 '25	Proposed Sale	191.53	549	105,150		Jul 23 04:01 PM

INCY

NOTV

CRL

OABI

NRC

MEDP

MXCT

IQV

Upgrade your FINVIZ experience